# Incretin Atlas — full text export Medical Adviser's Group. Data cut 12 November 2026; built 16 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/ Data: https://doi.org/10.5281/zenodo.23473913 (CC BY 4.0). Weight = percent change from baseline, drug vs placebo/comparator; eff = efficacy estimand, tp = treatment-policy estimand; pp = percentage points. ## Molecules ### Semaglutide (Wegovy / Ozempic / Rybelsus) — https://docs.mdwrt.app/infographics/incretin-atlas/semaglutide/ Mechanism: GLP-1. Route: s.c. / oral. Company: Novo Nordisk. Stage: approved. Status: Approved: obesity, T2D, MACE reduction, CKD in T2D (Ozempic), MASH (Wegovy US 2025; Kayshild EU 2026); oral Wegovy tablets. Next: 7.2 mg (STEP UP). Indications: Obesity: 4 (approved / in label) — FDA: Wegovy (injection and tablets); EMA: Wegovy; T2D: 4 (approved / in label) — FDA: Ozempic, Rybelsus; EMA: Ozempic, Rybelsus; CV outcomes: 4 (approved / in label) — FDA label: MACE reduction in T2D with CVD (Ozempic, SUSTAIN-6/SOUL) and in obesity with CVD (Wegovy, SELECT); CKD: 4 (approved / in label) — FDA label (Ozempic): reduce risk of kidney failure, eGFR decline and CV death in T2D with CKD; HFpEF: 3 (positive phase 3) — Positive phase 3 on symptoms and function; not a labelled indication; MASH: 4 (approved / in label) — FDA: Wegovy, accelerated approval (MASH F2–F3, 2025); EMA: Kayshild (2026); NMPA (China): Wegovy, September 2026; Sleep apnoea: 0 (no data) — No phase 3 in sleep apnoea registered; Knee OA: 3 (positive phase 3) — Positive phase 3 (pain and weight); not a labelled indication; Alzheimer's: -1 (negative phase 3/4) — evoke and evoke+ did not meet the primary endpoint - STEP 1: semaglutide 2.4 mg | pop obesity | 68 wk | n=1961 | weight eff -16.9 vs -2.4 % | weight tp -14.9 vs -2.4 % | HbA1c pp -0.45 vs -0.15 | AE d/c % 7.0 vs 3.1 | nausea % 44.2 vs 17.4 | vomiting % 24.8 vs 6.6 | SAE % 9.8 vs 6.4 | SBP mmHg -6.2 vs -1.1 | status verified-2 | src Wilding et al., NEJM 2021 https://pubmed.ncbi.nlm.nih.gov/33567185/; NCT03548935 https://clinicaltrials.gov/study/NCT03548935 - STEP UP: semaglutide 7.2 mg | pop obesity | 72 wk | n=1407 | weight eff -20.7 vs -2.4 % | weight tp -18.7 vs -3.9 % | HbA1c pp -0.32 vs -0.02 | AE d/c % 5.4 vs 1.0 | any d/c % 11.62 vs 29.38 | SAE % 6.8 vs 5.5 | SBP mmHg -9.9 vs -4.4 | status verified-2 | src NCT05646706 https://clinicaltrials.gov/study/NCT05646706; PubMed: STEP UP (Lancet Diabetes Endocrinol 2025) https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide+7.2+mg+STEP+UP - STEP UP: semaglutide 2.4 mg | pop obesity | 72 wk | n=1407 | weight eff -17.5 vs -2.4 % | weight tp -15.6 vs -3.9 % | HbA1c pp -0.3 vs -0.02 | AE d/c % 4.0 vs 1.0 | any d/c % 11.94 vs 29.35 | SAE % 10.9 vs 5.5 | SBP mmHg -8.7 vs -4.4 | status verified-2 | src NCT05646706 https://clinicaltrials.gov/study/NCT05646706 - STEP 2: semaglutide 2.4 mg | pop t2d | 68 wk | n=1210 | weight eff -10.6 vs -3.1 % | weight tp -9.64 vs -3.42 % | HbA1c pp -1.6 vs -0.4 | AE d/c % 6.2 vs 3.5 | any d/c % 11.6 vs 13.9 | nausea % 33.7 vs 9.2 | vomiting % 21.8 vs 2.7 | SAE % 9.9 vs 9.2 | SBP mmHg -3.9 vs -0.5 | status verified-2 | src Davies et al., Lancet 2021 https://pubmed.ncbi.nlm.nih.gov/33667417/; NCT03552757 https://clinicaltrials.gov/study/NCT03552757 - OASIS 4: oral semaglutide 25 mg | pop obesity | 64 wk | n=307 | weight eff -16.6 vs -2.7 % | weight tp -13.6 vs -2.2 % | HbA1c pp -0.3 vs -0.1 | AE d/c % 6.9 vs 5.9 | any d/c % 18.5 vs 25.5 | nausea % 46.6 vs 18.6 | vomiting % 30.9 vs 5.9 | SAE % 3.9 vs 8.8 | SBP mmHg -6.8 vs -5.4 | status verified-2 | src NCT05564117 https://clinicaltrials.gov/study/NCT05564117; PubMed: OASIS 4 (NEJM 2025) https://pubmed.ncbi.nlm.nih.gov/?term=oral+semaglutide+25+mg+OASIS+4 - CVOT SELECT (Obesity + established CVD, no diabetes, n=17604, 2023): 3-point MACE HR 0.8 (0.72–0.9); Cardiovascular death HR 0.85 (0.71–1.01); All-cause death HR 0.81 (0.71–0.93); Myocardial infarction HR 0.72 (0.61–0.85); Stroke HR 0.93 (0.74–1.15); Hospitalisation for heart failure HR 0.79 (0.6–1.03); CV death or worsening HF HR 0.82 (0.71–0.96); Kidney composite HR 0.78 (0.63–0.96); Expanded MACE (MACE + revasc. + UA) HR 0.8 (0.73–0.87); New-onset diabetes HR 0.27 (0.24–0.31); Coronary revascularisation HR 0.77 (0.68–0.87); Hospitalisation for unstable angina HR 0.87 (0.67–1.13) | src https://pubmed.ncbi.nlm.nih.gov/37952131/; https://clinicaltrials.gov/study/NCT03574597 - CVOT FLOW (T2D + CKD, n=3533, 2024): 3-point MACE HR 0.82 (0.68–0.98); Cardiovascular death HR 0.71 (0.56–0.89); All-cause death HR 0.8 (0.67–0.95); Myocardial infarction HR 0.8 (0.55–1.15); Stroke HR 1.22 (0.84–1.77); Major kidney disease events HR 0.76 (0.66–0.88); Sustained eGFR decline (≥50 %) HR 0.73 (0.59–0.89); Kidney failure (eGFR <15) HR 0.8 (0.61–1.06); Kidney failure (kidney-replacement therapy) HR 0.84 (0.63–1.12); Major adverse limb events HR 0.56 (0.3–1.02) | src https://pubmed.ncbi.nlm.nih.gov/38785209/; https://clinicaltrials.gov/study/NCT03819153 - CVOT SOUL (T2D + CVD/CKD, n=9650, 2025): 3-point MACE HR 0.86 (0.77–0.96); Cardiovascular death HR 0.93 (0.8–1.09); All-cause death HR 0.91 (0.8–1.02); Myocardial infarction HR 0.73 (0.61–0.88); Stroke HR 0.95 (0.76–1.17); Hospitalisation for heart failure HR 0.86 (0.69–1.08); CV death or worsening HF HR 0.9 (0.79–1.03); Kidney composite HR 0.91 (0.8–1.05); Expanded MACE (MACE + revasc. + UA) HR 0.84 (0.76–0.93); Major adverse limb events HR 0.71 (0.52–0.96); Coronary revascularisation HR 0.75 (0.62–0.9); Hospitalisation for unstable angina HR 0.92 (0.67–1.26) | src https://pubmed.ncbi.nlm.nih.gov/40162642/; https://clinicaltrials.gov/study/NCT03914326 - CVOT SUSTAIN-6 (T2D at high CV risk, n=3297, 2016): 3-point MACE HR 0.74 (0.58–0.95); Cardiovascular death HR 0.98 (0.65–1.48); All-cause death HR 1.05 (0.74–1.5); Myocardial infarction HR 0.74 (0.51–1.08); Stroke HR 0.61 (0.38–0.99); Hospitalisation for heart failure HR 1.11 (0.77–1.61); Kidney composite HR 0.64 (0.46–0.88); Expanded MACE (MACE + HF hosp. + revasc. + UA) HR 0.74 (0.62–0.89); Retinopathy complications HR 1.76 (1.11–2.78); Coronary revascularisation HR 0.65 (0.5–0.86); Hospitalisation for unstable angina HR 0.82 (0.47–1.44) | src https://pubmed.ncbi.nlm.nih.gov/27633186/ - CVOT PIONEER 6 (T2D at high CV risk, n=3183, 2019): 3-point MACE HR 0.79 (0.57–1.11); Cardiovascular death HR 0.49 (0.27–0.92); All-cause death HR 0.51 (0.31–0.84); Myocardial infarction HR 1.18 (0.73–1.9); Stroke HR 0.74 (0.35–1.57); Hospitalisation for heart failure HR 0.86 (0.48–1.55); Expanded MACE (MACE + HF hosp. + UA) HR 0.82 (0.61–1.1); Hospitalisation for unstable angina HR 1.56 (0.6–4.01) | src https://pubmed.ncbi.nlm.nih.gov/31185157/ - STEP-HFpEF (HFpEF + obesity, n=529, 52 wk): KCCQ-CSS +7.8 points vs placebo; weight −13.3 % vs −2.6 % | status seed | src https://pubmed.ncbi.nlm.nih.gov/37622681/ - STEP-HFpEF DM (HFpEF + obesity + T2D, n=616, 52 wk): KCCQ-CSS +7.3 points vs placebo | status seed | src https://pubmed.ncbi.nlm.nih.gov/38587233/ - STEP 9 (Knee osteoarthritis + obesity, n=407, 68 wk): WOMAC pain −41.7 vs −27.5 points; weight −13.7 % vs −3.2 % | status seed | src https://pubmed.ncbi.nlm.nih.gov/?term=semaglutide+STEP+9+knee+osteoarthritis - ESSENCE (part 1) (MASH F2–F3, n=800, 72 wk): Steatohepatitis resolution 62.9 % vs 34.3 %; fibrosis improvement 36.8 % vs 22.4 %; FDA accelerated approval 2025 | status seed | src https://pubmed.ncbi.nlm.nih.gov/40305708/ - FLOW (CKD + T2D, n=3533, 178 wk): Major kidney events HR 0.76; all-cause death HR 0.80 | status seed | src https://clinicaltrials.gov/study/NCT03819153; https://pubmed.ncbi.nlm.nih.gov/38785209/ - evoke / evoke+ (Early Alzheimer's disease, n=3680, 104 wk): Primary endpoint (CDR-SB) not met (announced Nov 2025) | status seed | src https://clinicaltrials.gov/study/NCT04777396; https://clinicaltrials.gov/study/NCT04777409; https://pubmed.ncbi.nlm.nih.gov/41865758/ ### Tirzepatide (Zepbound / Mounjaro) — https://docs.mdwrt.app/infographics/incretin-atlas/tirzepatide/ Mechanism: GIP/GLP-1. Route: s.c.. Company: Eli Lilly. Stage: approved. Status: Approved: obesity, T2D, obstructive sleep apnoea (FDA); MACE reduction added to the Mounjaro US label (2026). Next: HFpEF (SUMMIT) and MMO outcomes. Indications: Obesity: 4 (approved / in label) — FDA: Zepbound; EMA: Mounjaro (weight management); T2D: 4 (approved / in label) — FDA and EMA: Mounjaro; CV outcomes: 4 (approved / in label) — FDA label (Mounjaro, 2026): MACE reduction in T2D at high CV risk, based on SURPASS-CVOT; CKD: 1 (phase 2 / signal) — Phase 2 kidney study and kidney secondary analyses of SURPASS-CVOT; no dedicated phase 3; HFpEF: 3 (positive phase 3) — Positive phase 3 (CV death or worsening HF); EU label cites results in section 5.1, not as an indication; MASH: 2 (phase 3 ongoing) — Phase 2 positive (SYNERGY-NASH); phase 3 ongoing; Sleep apnoea: 4 (approved / in label) — FDA: Zepbound for moderate-to-severe OSA in adults with obesity; Knee OA: 2 (phase 3 ongoing) — Phase 3 ongoing; Alzheimer's: 0 (no data) — - SURMOUNT-1: tirzepatide 5 mg | pop obesity | 72 wk | n=2539 | weight eff -16.0 vs -2.4 % | weight tp -15.0 vs -3.1 % | AE d/c % 4.3 vs 2.6 | nausea % 24.6 vs 9.5 | vomiting % 8.3 vs 1.7 | SAE % 6.3 vs 6.8 | status verified-2 | src Jastreboff et al., NEJM 2022 https://pubmed.ncbi.nlm.nih.gov/35658024/; NCT04184622 https://clinicaltrials.gov/study/NCT04184622 - SURMOUNT-1: tirzepatide 10 mg | pop obesity | 72 wk | n=2539 | weight eff -21.4 vs -2.4 % | weight tp -19.5 vs -3.1 % | AE d/c % 7.1 vs 2.6 | nausea % 33.3 vs 9.5 | vomiting % 10.7 vs 1.7 | SAE % 6.9 vs 6.8 | status verified-2 | src Jastreboff et al., NEJM 2022 https://pubmed.ncbi.nlm.nih.gov/35658024/ - SURMOUNT-1: tirzepatide 15 mg | pop obesity | 72 wk | n=2539 | weight eff -22.5 vs -2.4 % | weight tp -20.9 vs -3.1 % | AE d/c % 6.2 vs 2.6 | nausea % 31.0 vs 9.5 | vomiting % 12.2 vs 1.7 | SAE % 5.1 vs 6.8 | status verified-2 | src Jastreboff et al., NEJM 2022 https://pubmed.ncbi.nlm.nih.gov/35658024/ - SURMOUNT-2: tirzepatide 15 mg | pop t2d | 72 wk | n=938 | weight eff -15.7 vs -3.3 % | weight tp -14.7 vs -3.2 % | HbA1c pp -2.08 vs -0.51 | AE d/c % 7.4 vs 3.8 | any d/c % 13.8 vs 14.9 | nausea % 21.9 vs 6.3 | vomiting % 13.2 vs 3.2 | SAE % 8.7 vs 7.3 | status verified-2 | src Garvey et al., Lancet 2023 https://pubmed.ncbi.nlm.nih.gov/37385275/; NCT04657003 https://clinicaltrials.gov/study/NCT04657003 - SURMOUNT-2: tirzepatide 10 mg | pop t2d | 72 wk | n=938 | weight eff -13.4 vs -3.3 % | weight tp -12.8 vs -3.2 % | HbA1c pp -2.1 vs -0.5 | AE d/c % 3.8 vs 3.8 | any d/c % 9.3 vs 14.9 | nausea % 20.2 vs 6.3 | vomiting % 10.9 vs 3.2 | SAE % 5.8 vs 7.3 | status verified-2 | src Garvey et al., Lancet 2023 https://pubmed.ncbi.nlm.nih.gov/37385275/ - SURMOUNT-5 (head-to-head): tirzepatide 10/15 mg | pop obesity | 72 wk | n=751 | weight eff -21.6 vs None % | weight tp -20.2 vs None % | AE d/c % 6.1 vs None | any d/c % 18.4 vs None | nausea % 43.6 vs None | vomiting % 15.0 vs None | SAE % 4.8 vs None | SBP mmHg -10.2 vs None | status verified-2 | src NCT05822830 https://clinicaltrials.gov/study/NCT05822830; PubMed: SURMOUNT-5 (NEJM 2025) https://pubmed.ncbi.nlm.nih.gov/?term=SURMOUNT-5+tirzepatide+semaglutide - EloraTZP phase 2b (obesity + T2D): tirzepatide 15 mg | pop t2d | 48 wk | n=None | weight eff -14.8 vs -3.0 % | HbA1c pp -2.4 vs -0.3 | AE d/c % 2.9 vs 16.7 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html - CVOT SURPASS-CVOT (T2D + established ASCVD, n=13299, 2025): 3-point MACE (vs dulaglutide) HR 0.92 (0.83–1.01); Cardiovascular death HR 0.89 (0.77–1.02); All-cause death HR 0.84 (0.75–0.94); Myocardial infarction HR 0.86 (0.74–1.0); Stroke HR 0.91 (0.76–1.09); CV death or worsening HF HR 0.91 (0.81–1.03); Expanded MACE (MACE + revasc.) HR 0.88 (0.81–0.96) | src https://pubmed.ncbi.nlm.nih.gov/41406444/; https://clinicaltrials.gov/study/NCT04255433; https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - CVOT SUMMIT (HFpEF + obesity, n=731, 2024): Cardiovascular death HR 1.58 (0.52–4.83); All-cause death HR 1.25 (0.63–2.45); Hospitalisation for heart failure HR 0.44 (0.22–0.87); CV death or worsening HF HR 0.62 (0.41–0.95) | src https://pubmed.ncbi.nlm.nih.gov/39555826/; https://clinicaltrials.gov/study/NCT04847557 - SUMMIT (HFpEF + obesity, n=731, 104 wk): CV death or worsening HF HR 0.62; KCCQ-CSS +6.9 points | status seed | src https://clinicaltrials.gov/study/NCT04847557; https://pubmed.ncbi.nlm.nih.gov/39555826/ - SURMOUNT-OSA (Obstructive sleep apnoea + obesity, n=469, 52 wk): AHI −25.3 vs −5.3 events/h (trial 1), −29.3 vs −5.5 (trial 2, on PAP); FDA label Dec 2024 | status seed | src https://pubmed.ncbi.nlm.nih.gov/38912654/ - SYNERGY-NASH (MASH F2–F3, n=190, 52 wk): MASH resolution without worsening fibrosis 44–62 % vs 10 % | status seed | src https://pubmed.ncbi.nlm.nih.gov/38856224/ ### Liraglutide (Saxenda / generics) — https://docs.mdwrt.app/infographics/incretin-atlas/liraglutide/ Mechanism: GLP-1. Route: s.c. daily. Company: Novo Nordisk / generics. Stage: approved. Status: Approved for obesity (2014); generics available. Next: —. Indications: Obesity: 4 (approved / in label) — FDA and EMA: Saxenda; T2D: 4 (approved / in label) — FDA and EMA: Victoza; CV outcomes: 4 (approved / in label) — FDA label (Victoza): MACE reduction in T2D with established CVD; CKD: 1 (phase 2 / signal) — Kidney outcomes only as a LEADER secondary endpoint; no dedicated phase 3; HFpEF: 1 (phase 2 / signal) — Phase 2 only; MASH: 1 (phase 2 / signal) — Phase 2 only (LEAN); Sleep apnoea: 3 (positive phase 3) — Positive phase 3 (SCALE Sleep Apnea, results posted); not a labelled indication; Knee OA: -1 (negative phase 3/4) — LOSEIT (phase 4): no reduction in knee pain versus placebo after diet-induced weight loss; Alzheimer's: 1 (phase 2 / signal) — Phase 2b (ELAD) only - CVOT LEADER (T2D at high CV risk, n=9340, 2016): 3-point MACE HR 0.87 (0.78–0.97); Cardiovascular death HR 0.78 (0.66–0.93); All-cause death HR 0.85 (0.74–0.97); Myocardial infarction HR 0.86 (0.73–1.0); Stroke HR 0.86 (0.71–1.06); Hospitalisation for heart failure HR 0.87 (0.73–1.05); Kidney composite HR 0.78 (0.67–0.92); Expanded MACE (MACE + HF hosp. + revasc. + UA) HR 0.88 (0.81–0.96); Retinopathy complications HR 1.15 (0.87–1.52); Coronary revascularisation HR 0.91 (0.8–1.04); Hospitalisation for unstable angina HR 0.98 (0.76–1.26) | src https://pubmed.ncbi.nlm.nih.gov/27295427/ - ELAD (Mild cognitive impairment + T2D, n=396, 48 wk): MCI reversal 49.5 % vs 20.4 % on linagliptin (EASD 2026) | status easd | src https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; https://pubmed.ncbi.nlm.nih.gov/41326666/ ### Orforglipron (LY3502970) — https://docs.mdwrt.app/infographics/incretin-atlas/orforglipron/ Mechanism: GLP-1 (small molecule). Route: oral. Company: Eli Lilly. Stage: approved. Status: Approved in the US for obesity (Foundayo, 2026); T2D phase 3 positive (ACHIEVE). Next: T2D filing; CV outcomes trial ongoing. Indications: Obesity: 4 (approved / in label) — FDA: Foundayo (2026); T2D: 3 (positive phase 3) — Positive phase 3 programme (ACHIEVE); not yet labelled for T2D; CV outcomes: 3 (positive phase 3) — ACHIEVE-4 met MACE non-inferiority versus insulin glargine; a placebo-controlled CV outcomes trial is ongoing; CKD: 1 (phase 2 / signal) — Slower eGFR decline versus glargine as a secondary outcome in ACHIEVE-4; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 3 (positive phase 3) — Positive phase 3: ATTAIN-OSA (JAMA, Nov 2026); Knee OA: 2 (phase 3 ongoing) — Phase 3 ongoing; Alzheimer's: 0 (no data) — - ATTAIN-1: orforglipron 36 mg | pop obesity | 72 wk | n=3127 | weight eff -12.4 vs -0.9 % | weight tp -11.2 vs -2.1 % | AE d/c % 10.3 vs 2.7 | any d/c % 24.4 vs 29.9 | SAE % 3.8 vs 4.9 | status verified-2 | src NCT05869903 https://clinicaltrials.gov/study/NCT05869903; PubMed: ATTAIN-1 (NEJM 2025) https://pubmed.ncbi.nlm.nih.gov/?term=orforglipron+ATTAIN-1 - ATTAIN-2 (obesity + T2D): orforglipron 6 mg | pop t2d | 72 wk | n=1613 | weight eff -5.5 vs -2.2 % | weight tp -5.1 vs -2.5 % | HbA1c pp -1.22 vs -0.47 | AE d/c % 6.1 vs 4.6 | any d/c % 19.1 vs 20.0 | nausea % 20.1 vs 8.4 | vomiting % 12.8 vs 3.8 | SAE % 7.3 vs 8.8 | status verified-2 | src Horn DB et al. Lancet 2025 (ATTAIN-2) https://pubmed.ncbi.nlm.nih.gov/41275875/; ATTAIN-2 (NCT05872620) https://clinicaltrials.gov/study/NCT05872620 - ATTAIN-2 (obesity + T2D): orforglipron 12 mg | pop t2d | 72 wk | n=1613 | weight eff -7.8 vs -2.2 % | weight tp -7.0 vs -2.5 % | HbA1c pp -1.5 vs -0.47 | AE d/c % 10.6 vs 4.6 | any d/c % 22.3 vs 20.0 | nausea % 31.1 vs 8.4 | vomiting % 20.2 vs 3.8 | SAE % 10.3 vs 8.8 | status verified-2 | src Horn DB et al. Lancet 2025 (ATTAIN-2) https://pubmed.ncbi.nlm.nih.gov/41275875/; ATTAIN-2 (NCT05872620) https://clinicaltrials.gov/study/NCT05872620 - ATTAIN-2 (obesity + T2D): orforglipron 36 mg | pop t2d | 72 wk | n=1613 | weight eff -10.5 vs -2.2 % | weight tp -9.6 vs -2.5 % | HbA1c pp -1.66 vs -0.47 | AE d/c % 10.6 vs 4.6 | any d/c % 20.5 vs 20.0 | nausea % 36.4 vs 8.4 | vomiting % 23.1 vs 3.8 | SAE % 10.9 vs 8.8 | status verified-2 | src Horn DB et al. Lancet 2025 (ATTAIN-2) https://pubmed.ncbi.nlm.nih.gov/41275875/; ATTAIN-2 (NCT05872620) https://clinicaltrials.gov/study/NCT05872620 - ACHIEVE-1: orforglipron 36 mg | pop t2d | 40 wk | n=559 | weight eff -7.9 vs -1.6 % | weight tp -7.6 vs -1.7 % | HbA1c pp -1.48 vs -0.41 | AE d/c % 7.8 vs 1.4 | any d/c % 9.9 vs 7.2 | nausea % 16.3 vs 2.2 | vomiting % 14.2 vs 1.4 | SAE % 2.8 vs 3.6 | status verified-2 | src NCT05971940 https://clinicaltrials.gov/study/NCT05971940; PubMed: ACHIEVE-1 (NEJM 2025) https://pubmed.ncbi.nlm.nih.gov/?term=orforglipron+ACHIEVE-1 - ACHIEVE-4 (vs insulin glargine): orforglipron 36 mg or MTD | pop t2d | 52 wk | n=None | weight eff -8.76 vs None % | weight tp -7.79 vs None % | HbA1c pp -1.46 vs None | AE d/c % 15.4 vs None | any d/c % 30.9 vs 20.5 | nausea % 31.9 vs None | vomiting % 21.0 vs None | SAE % 16.2 vs None | status verified-2 | src ACHIEVE-4, 2026 https://pubmed.ncbi.nlm.nih.gov/42815506/ - ACHIEVE-2 (vs dapagliflozin): orforglipron 3 mg | pop t2d | 40 wk | n=240 | weight (estimand n/s) -3.5 vs None % | HbA1c pp -1.32 vs None | nausea % 19.6 vs None | vomiting % 7.9 vs None | SAE % 3.3 vs None | status verified-2 | src ACHIEVE-2 results posted on ClinicalTrials.gov (NCT06192108) https://clinicaltrials.gov/study/NCT06192108?tab=results - ACHIEVE-2 (vs dapagliflozin): orforglipron 12 mg | pop t2d | 40 wk | n=241 | weight (estimand n/s) -6.3 vs None % | HbA1c pp -1.74 vs None | nausea % 17.8 vs None | vomiting % 8.3 vs None | SAE % 5.8 vs None | status verified-2 | src ACHIEVE-2 results posted on ClinicalTrials.gov (NCT06192108) https://clinicaltrials.gov/study/NCT06192108?tab=results - ACHIEVE-2 (vs dapagliflozin): orforglipron 36 mg | pop t2d | 40 wk | n=241 | weight (estimand n/s) -7.3 vs None % | HbA1c pp -1.73 vs None | nausea % 22.4 vs None | vomiting % 12.0 vs None | SAE % 4.1 vs None | status verified-2 | src ACHIEVE-2 results posted on ClinicalTrials.gov (NCT06192108) https://clinicaltrials.gov/study/NCT06192108?tab=results - ATTAIN-J (Japan): orforglipron 6 mg | pop obesity | 72 wk | n=61 | weight tp -5.9 vs -0.6 % | status verified-2 | src ATTAIN-J, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42962687/ - ATTAIN-J (Japan): orforglipron 12 mg | pop obesity | 72 wk | n=57 | weight tp -8.7 vs -0.6 % | status verified-2 | src ATTAIN-J, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42962687/ - ATTAIN-J (Japan): orforglipron 36 mg | pop obesity | 72 wk | n=60 | weight tp -7.9 vs -0.6 % | status verified-2 | src ATTAIN-J, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42962687/ - CVOT ACHIEVE-4 (T2D at increased CV risk (86 % established CVD, 38 % CKD), n=2749, 2026): 4-point MACE HR 0.84 (0.59–1.2); 3-point MACE HR 0.77 (0.52–1.13); Cardiovascular death HR 0.47 (0.25–0.9); Myocardial infarction HR 0.85 (0.46–1.58); Stroke HR 0.98 (0.47–2.06); Hospitalisation for unstable angina HR 1.55 (0.67–3.58) | src https://pubmed.ncbi.nlm.nih.gov/42815506/; https://clinicaltrials.gov/study/NCT05803421 - ATTAIN-OSA trial 1 / trial 2 (Obstructive sleep apnoea + obesity or overweight (no T2D), n=712, 52 wk): AHI −13.2 (trial 1, no PAP) and −12.0 (trial 2, on PAP) events/h vs placebo at 52 weeks, treatment-regimen estimand; 6 of 7 key secondary end points significant. | status abstract | src https://pubmed.ncbi.nlm.nih.gov/43002161/; https://clinicaltrials.gov/study/NCT06649045 ### CagriSema (cagrilintide + semaglutide) — https://docs.mdwrt.app/infographics/incretin-atlas/cagrisema/ Mechanism: GLP-1 + amylin. Route: s.c.. Company: Novo Nordisk. Stage: phase 3. Status: Phase 3 (REDEFINE); filing 2026. Next: REDEFINE 3 (CV outcomes), REIMAGINE (T2D). Indications: Obesity: 3 (positive phase 3) — Positive phase 3; NDA under FDA review (submitted 18 December 2025); T2D: 3 (positive phase 3) — Positive phase 3; CV outcomes: 2 (phase 3 ongoing) — REDEFINE 3 ongoing; CKD: 1 (phase 2 / signal) — Phase 2 only; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - REDEFINE 1: CagriSema 2.4/2.4 mg | pop obesity | 68 wk | n=3417 | weight eff -22.7 vs -2.3 % | weight tp -20.4 vs -3.0 % | AE d/c % 5.9 vs 3.5 | any d/c % 11.8 vs 24.1 | SAE % 9.8 vs 6.1 | SBP mmHg -9.9 vs -3.2 | status verified-2 | src NCT05567796 https://clinicaltrials.gov/study/NCT05567796; PubMed: REDEFINE 1 (NEJM 2025) https://pubmed.ncbi.nlm.nih.gov/?term=REDEFINE+1+cagrilintide+semaglutide - REDEFINE 2: CagriSema 2.4/2.4 mg | pop t2d | 68 wk | n=1206 | weight eff -15.7 vs -3.1 % | weight tp -13.7 vs -3.4 % | HbA1c pp -1.8 vs -0.4 | AE d/c % 8.4 vs 3.0 | SAE % 10.4 vs 12.9 | SBP mmHg -6.5 vs -2.4 | status verified-2 | src Davies MJ et al. N Engl J Med 2025 (REDEFINE 2) https://pubmed.ncbi.nlm.nih.gov/40544432/; NCT05394519 https://clinicaltrials.gov/study/NCT05394519 - REIMAGINE 1 (early T2D): CagriSema 2.4/2.4 mg | pop t2d | 40 wk | n=189 | weight eff -14.3 vs -2.8 % | weight tp -14.3 vs -2.8 % | status verified-2 | src EASD 2026, abstract 66750 (LBA) https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - REDEFINE 5 (vs semaglutide 2.4 mg): CagriSema 2.4/2.4 mg | pop obesity | 68 wk | n=164 | weight eff -18.4 vs None % | weight tp -16.9 vs None % | HbA1c pp -1.1 vs None | AE d/c % 2.0 vs None | any d/c % 10.0 vs None | SAE % 4.0 vs None | SBP mmHg -10.0 vs None | status verified-2 | src REDEFINE 5, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42009015/ - REIMAGINE 5 (vs tirzepatide 5 mg): CagriSema 1.0/1.0 mg | pop t2d | 60 wk | n=None | weight eff -12.4 vs None % | HbA1c pp -1.71 vs None | status press | src Novo Nordisk. CagriSema REIMAGINE 5 and REDEFINE 9 topline results [company announcement]. 2026 Sep 21 https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916774 - REDEFINE 9: CagriSema 1.0/1.0 mg | pop obesity | 68 wk | n=None | weight eff -21.0 vs -2.0 % | status press | src Novo Nordisk. CagriSema REIMAGINE 5 and REDEFINE 9 topline results [company announcement]. 2026 Sep 21 https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916774 ### Retatrutide (LY3437943) — https://docs.mdwrt.app/infographics/incretin-atlas/retatrutide/ Mechanism: GIP/GLP-1/GCG. Route: s.c.. Company: Eli Lilly. Stage: phase 3. Status: Phase 3 positive: TRIUMPH-1 (NEJM 2026), TRIUMPH-2/-3 and TRIUMPH-4 toplines; TRANSCEND-T2D-1 at EASD 2026. Next: US submission planned Q1 2027. Indications: Obesity: 3 (positive phase 3) — Positive phase 3 (TRIUMPH-1 published; TRIUMPH-3 topline); US submission planned Q1 2027; T2D: 3 (positive phase 3) — Positive phase 3 (TRANSCEND-T2D-1; TRIUMPH-2 HbA1c); CV outcomes: 2 (phase 3 ongoing) — CV and kidney outcomes trial ongoing; CKD: 2 (phase 3 ongoing) — Phase 3 ongoing; HFpEF: 0 (no data) — ; MASH: 2 (phase 3 ongoing) — Phase 3 ongoing; Sleep apnoea: 3 (positive phase 3) — Positive phase 3: TRIUMPH-1-OSA and TRIUMPH-2-OSA (NEJM 2026); Knee OA: 3 (positive phase 3) — Positive phase 3: TRIUMPH-4 and TRIUMPH-1-OA (NEJM, Nov 2026); Alzheimer's: 0 (no data) — - Retatrutide phase 2 (obesity): retatrutide 12 mg | pop obesity | 48 wk | n=338 | weight eff -24.2 vs -2.1 % | AE d/c % 16.0 vs 0.0 | nausea % 45.0 vs 11.0 | vomiting % 19.0 vs 1.0 | SAE % 3.0 vs 4.0 | status verified-2 | src Jastreboff et al., NEJM 2023 https://pubmed.ncbi.nlm.nih.gov/37366315/; NCT04881760 https://clinicaltrials.gov/study/NCT04881760 - Retatrutide phase 2 (obesity): retatrutide 8 mg (start 4 mg) | pop obesity | 48 wk | n=338 | weight eff -23.9 vs -2.1 % | AE d/c % 6.0 vs 0.0 | nausea % 60.0 vs 11.0 | vomiting % 26.0 vs 1.0 | SAE % 6.0 vs 4.0 | status verified-2 | src Jastreboff et al., NEJM 2023 https://pubmed.ncbi.nlm.nih.gov/37366315/ - Retatrutide phase 2 (obesity): retatrutide 4 mg (start 4 mg) | pop obesity | 48 wk | n=338 | weight eff -17.8 vs -2.1 % | AE d/c % 9.0 vs 0.0 | nausea % 36.0 vs 11.0 | vomiting % 12.0 vs 1.0 | SAE % 6.0 vs 4.0 | status verified-2 | src Jastreboff et al., NEJM 2023 https://pubmed.ncbi.nlm.nih.gov/37366315/ - Retatrutide phase 2 (T2D): retatrutide 12 mg | pop t2d | 36 wk | n=281 | weight eff -16.9 vs -3.0 % | HbA1c pp -2.0 vs 0.0 | status seed | src Rosenstock et al., Lancet 2023 https://pubmed.ncbi.nlm.nih.gov/37385280/ - TRANSCEND-T2D-1 (T2D monotherapy): retatrutide 12 mg | pop t2d | 40 wk | n=537 | weight eff -16.8 vs -2.5 % | weight tp -16.8 vs -2.5 % | HbA1c pp -1.9 vs -0.8 | AE d/c % 5.1 vs 0.0 | status verified-2 | src EASD 2026, abstract 64085 (OP 03) https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - TRIUMPH-1: retatrutide 4 mg | pop obesity | 80 wk | n=584 | weight eff -19.0 vs -2.2 % | weight tp -17.6 vs -3.9 % | AE d/c % 4.1 vs 4.6 | nausea % 28.6 vs 14.8 | vomiting % 10.6 vs 4.8 | SAE % 7.7 vs 5.5 | SBP mmHg -7.6 vs -1.9 | status verified-2 | src TRIUMPH-1, NEJM 2026 https://pubmed.ncbi.nlm.nih.gov/42814954/ - TRIUMPH-1: retatrutide 9 mg | pop obesity | 80 wk | n=584 | weight eff -25.9 vs -2.2 % | weight tp -23.7 vs -3.9 % | AE d/c % 6.5 vs 4.6 | nausea % 38.4 vs 14.8 | vomiting % 22.8 vs 4.8 | SAE % 7.7 vs 5.5 | SBP mmHg -9.8 vs -1.9 | status verified-2 | src TRIUMPH-1, NEJM 2026 https://pubmed.ncbi.nlm.nih.gov/42814954/ - TRIUMPH-1: retatrutide 12 mg | pop obesity | 80 wk | n=584 | weight eff -28.3 vs -2.2 % | weight tp -25.0 vs -3.9 % | AE d/c % 11.2 vs 4.6 | nausea % 42.4 vs 14.8 | vomiting % 25.3 vs 4.8 | SAE % 10.5 vs 5.5 | SBP mmHg -10.4 vs -1.9 | status verified-2 | src TRIUMPH-1, NEJM 2026 https://pubmed.ncbi.nlm.nih.gov/42814954/ - TRIUMPH-4 (obesity + knee osteoarthritis): retatrutide 9 mg | pop obesity | 68 wk | n=148 | weight eff -26.4 vs -2.1 % | weight tp -20.0 vs -4.6 % | AE d/c % 12.9 vs 4.0 | SAE % 9.5 vs 2.0 | status verified-2 | src Schnitzer TJ et al. N Engl J Med 2026 (TRIUMPH-4 and TRIUMPH-1-OA) https://pubmed.ncbi.nlm.nih.gov/43001755/; Eli Lilly and Company. TRIUMPH-4 topline results [press release coverage]. 2025 Dec 11 https://www.pharmexec.com/view/lilly-retatrutide-positive-topline-results-successful-phase-iii-trial; Retatrutide achieves up to 28.7% weight loss and marked knee pain reduction in phase 3 TRIUMPH-4 trial. Patient Care. 2025 Dec 11 https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial - TRIUMPH-4 (obesity + knee osteoarthritis): retatrutide 12 mg | pop obesity | 68 wk | n=148 | weight eff -28.7 vs -2.1 % | weight tp -23.7 vs -4.6 % | AE d/c % 18.2 vs 4.0 | SAE % 10.8 vs 2.0 | SBP mmHg -14.0 vs None | status verified-2 | src Schnitzer TJ et al. N Engl J Med 2026 (TRIUMPH-4 and TRIUMPH-1-OA) https://pubmed.ncbi.nlm.nih.gov/43001755/; Eli Lilly and Company. TRIUMPH-4 topline results [press release coverage]. 2025 Dec 11 https://www.pharmexec.com/view/lilly-retatrutide-positive-topline-results-successful-phase-iii-trial; Retatrutide achieves up to 28.7% weight loss and marked knee pain reduction in phase 3 TRIUMPH-4 trial. Patient Care. 2025 Dec 11 https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial - TRIUMPH-2 (obesity + T2D): retatrutide 4 mg | pop t2d | 80 wk | n=None | weight eff -12.7 vs -4.0 % | weight tp -11.9 vs -5.1 % | HbA1c pp -1.38 vs -0.45 | AE d/c % 3 vs 5 | any d/c % 10.3 vs 21.5 | nausea % 14 vs 8 | vomiting % 6 vs 4 | SAE % 8 vs 8 | SBP mmHg -5.0 vs -2.7 | status verified-2 | src TRIUMPH-2, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42810372/ - TRIUMPH-2 (obesity + T2D): retatrutide 9 mg | pop t2d | 80 wk | n=None | weight eff -19.1 vs -4.0 % | weight tp -16.8 vs -5.1 % | HbA1c pp -1.5 vs -0.45 | AE d/c % 11 vs 5 | any d/c % 19.4 vs 21.5 | nausea % 21 vs 8 | vomiting % 10 vs 4 | SAE % 9 vs 8 | SBP mmHg -7.4 vs -2.7 | status verified-2 | src TRIUMPH-2, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42810372/ - TRIUMPH-2 (obesity + T2D): retatrutide 12 mg | pop t2d | 80 wk | n=None | weight eff -20.8 vs -4.0 % | weight tp -18.8 vs -5.1 % | HbA1c pp -1.45 vs -0.45 | AE d/c % 7 vs 5 | any d/c % 13.9 vs 21.5 | nausea % 28 vs 8 | vomiting % 16 vs 4 | SAE % 9 vs 8 | SBP mmHg -9.7 vs -2.7 | status verified-2 | src TRIUMPH-2, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42810372/ - TRANSCEND-T2D-2 (vs semaglutide 2 mg): retatrutide 9 mg | pop t2d | 80 wk | n=None | weight eff -19.5 vs None % | HbA1c pp -2.2 vs None | AE d/c % 4.8 vs None | nausea % 21.2 vs None | vomiting % 10.2 vs None | status press | src Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial [press release]. Indianapolis (IN): Eli Lilly and Company; 2026 Oct 28 https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html - TRANSCEND-T2D-2 (vs semaglutide 2 mg): retatrutide 12 mg | pop t2d | 80 wk | n=None | weight eff -20.9 vs None % | HbA1c pp -2.2 vs None | AE d/c % 7.9 vs None | nausea % 23.8 vs None | vomiting % 15.0 vs None | status press | src Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial [press release]. Indianapolis (IN): Eli Lilly and Company; 2026 Oct 28 https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html - TRIUMPH-1-OSA / TRIUMPH-2-OSA (Obstructive sleep apnoea + obesity (with or without T2D), n=691, 80 wk): AHI −24.4 (9 mg) and −21.9 (12 mg) events/h vs placebo without T2D; −14.4 and −15.1 with T2D (hybrid estimand, primary). Sub-studies nested in TRIUMPH-1 and TRIUMPH-2. | status verified-2 | src https://pubmed.ncbi.nlm.nih.gov/42904878/ - TRIUMPH-4 / TRIUMPH-1-OA (Knee osteoarthritis + obesity, n=1019, 68 wk): WOMAC pain −1.83 (9 mg) and −1.61 (12 mg) points vs placebo on a 0–10 scale at 68 weeks in TRIUMPH-4; −1.35, −1.61 and −1.77 (4/9/12 mg) at 80 weeks in TRIUMPH-1-OA (hybrid-treatment estimand). Weight −15.4 and −19.2 percentage points vs placebo in TRIUMPH-4 (treatment-regimen estimand). | status verified-2 | src https://pubmed.ncbi.nlm.nih.gov/43001755/; https://clinicaltrials.gov/study/NCT05931367 ### Survodutide (BI 456906) — https://docs.mdwrt.app/infographics/incretin-atlas/survodutide/ Mechanism: GLP-1/GCG. Route: s.c.. Company: Boehringer Ingelheim / Zealand. Stage: phase 3. Status: Phase 3 positive in obesity (SYNCHRONIZE-1, NEJM 2026) and T2D (SYNCHRONIZE-2, NEJM 2026); SYNCHRONIZE-CVOT showed CV safety (non-inferior to placebo, Lancet Nov 2026). Next: MASH phase 3 (LIVERAGE). Indications: Obesity: 3 (positive phase 3) — Positive phase 3 (SYNCHRONIZE-1); regulatory submissions in preparation (Boehringer Ingelheim, November 2026); T2D: 3 (positive phase 3) — Positive phase 3 (SYNCHRONIZE-2, NEJM/EASD 2026); CV outcomes: 3 (positive phase 3) — SYNCHRONIZE-CVOT (Lancet, Nov 2026): CV safety shown — non-inferior to placebo for five-point MACE, HR 0.89 (0.67–1.18); not designed or powered for superiority; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 2 (phase 3 ongoing) — Phase 2 positive; phase 3 (LIVERAGE) ongoing; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - Survodutide phase 2 (obesity): survodutide 4.8 mg | pop obesity | 46 wk | n=387 | weight eff -18.7 vs -2.3 % | weight tp -14.9 vs -2.8 % | AE d/c % 29.0 vs 4.0 | any d/c % 39.0 vs 40.3 | nausea % 64.0 vs 20.0 | vomiting % 35.0 vs 5.0 | SAE % 5.0 vs 7.0 | SBP mmHg -8.6 vs -2.5 | status verified-2 | src NCT04667377 https://clinicaltrials.gov/study/NCT04667377; PubMed: le Roux et al., Lancet Diabetes Endocrinol 2024 https://pubmed.ncbi.nlm.nih.gov/?term=survodutide+obesity+phase+2+le+Roux - SYNCHRONIZE-1: survodutide 3.6 mg | pop obesity | 76 wk | n=241 | weight eff -15.3 vs -3.2 % | weight tp -12.2 vs -5.4 % | HbA1c pp -0.2 vs 0.0 | AE d/c % 23.7 vs 5.4 | any d/c % 35.3 vs 40.1 | nausea % 61.0 vs 17.4 | vomiting % 40.7 vs 6.2 | SAE % 8.3 vs 6.2 | SBP mmHg -6.7 vs -5.9 | status verified-2 | src SYNCHRONIZE-1, NEJM 2026 https://pubmed.ncbi.nlm.nih.gov/42253238/ - SYNCHRONIZE-1: survodutide 6.0 mg | pop obesity | 76 wk | n=242 | weight eff -16.6 vs -3.2 % | weight tp -13.0 vs -5.4 % | HbA1c pp -0.2 vs 0.0 | AE d/c % 24.8 vs 5.4 | any d/c % 34.3 vs 40.1 | nausea % 64.9 vs 17.4 | vomiting % 44.6 vs 6.2 | SAE % 8.3 vs 6.2 | SBP mmHg -5.4 vs -5.9 | status verified-2 | src SYNCHRONIZE-1, NEJM 2026 https://pubmed.ncbi.nlm.nih.gov/42253238/ - SYNCHRONIZE-2 (obesity + T2D): survodutide 3.6 mg | pop t2d | 76 wk | n=None | weight eff -10.4 vs -3.1 % | weight tp -8.2 vs -3.9 % | HbA1c pp -0.9 vs -0.2 | AE d/c % 26.4 vs 8.8 | any d/c % 36.0 vs 30.7 | nausea % 47.6 vs 11.2 | vomiting % 34.4 vs 5.6 | SAE % 9.2 vs 10.8 | SBP mmHg -3.5 vs -2.7 | status verified-2 | src SYNCHRONIZE-2, N Engl J Med 2026 https://pubmed.ncbi.nlm.nih.gov/42820639/ - SYNCHRONIZE-2 (obesity + T2D): survodutide 6.0 mg | pop t2d | 76 wk | n=None | weight eff -13.1 vs -3.1 % | weight tp -9.8 vs -3.9 % | HbA1c pp -0.8 vs -0.2 | AE d/c % 25.9 vs 8.8 | any d/c % 34.7 vs 30.7 | nausea % 57.4 vs 11.2 | vomiting % 39.0 vs 5.6 | SAE % 8.4 vs 10.8 | SBP mmHg -3.7 vs -2.7 | status verified-2 | src SYNCHRONIZE-2, N Engl J Med 2026 https://pubmed.ncbi.nlm.nih.gov/42820639/ - SYNCHRONIZE-CVOT: survodutide 3.6 mg | pop obesity | 72 wk | n=None | weight tp -9.3 vs -2.4 % | AE d/c % 28.2 vs 11.1 | any d/c % 44.0 vs 41.0 | nausea % 48.0 vs 12.1 | vomiting % 31.7 vs 4.8 | SAE % 22.5 vs 23.9 | SBP mmHg -4.29 vs -1.72 | status verified-2 | src Bozkurt B, le Roux CW, Wharton S, Butt JH, Startseva E, Sumin M, et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Nov 9. doi:10.1016/S0140-6736(26)02140-9 https://doi.org/10.1016/S0140-6736(26)02140-9 - SYNCHRONIZE-CVOT: survodutide 6.0 mg | pop obesity | 72 wk | n=None | weight tp -9.7 vs -2.4 % | AE d/c % 29.1 vs 11.1 | any d/c % 43.4 vs 41.0 | nausea % 49.0 vs 12.1 | vomiting % 34.0 vs 4.8 | SAE % 20.8 vs 23.9 | SBP mmHg -4.89 vs -1.72 | status verified-2 | src Bozkurt B, le Roux CW, Wharton S, Butt JH, Startseva E, Sumin M, et al. Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026 Nov 9. doi:10.1016/S0140-6736(26)02140-9 https://doi.org/10.1016/S0140-6736(26)02140-9 - CVOT SYNCHRONIZE-CVOT (Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD), n=5530, 2026): Expanded MACE HR 0.89 (0.67–1.18); 3-point MACE HR 0.84 (0.6–1.18); 4-point MACE HR 0.93 (0.67–1.29); Cardiovascular death HR 1.05 (0.49–2.23); All-cause death HR 1.2 (0.73–1.97); Myocardial infarction HR 0.99 (0.6–1.64); Stroke HR 0.72 (0.41–1.27); Heart failure event HR 0.76 (0.46–1.25); CV death or worsening HF HR 0.8 (0.52–1.22); Coronary revascularisation HR 2.49 (0.85–7.3); New-onset diabetes HR 0.28 (0.16–0.5) | src https://doi.org/10.1016/S0140-6736(26)02140-9; https://clinicaltrials.gov/study/NCT06077864 - Survodutide phase 2 MASH (MASH F1–F3, n=293, 48 wk): Histological improvement of MASH 83 % vs 18 % | status seed | src https://pubmed.ncbi.nlm.nih.gov/?term=survodutide+MASH+phase+2 ### Mazdutide (IBI362) — https://docs.mdwrt.app/infographics/incretin-atlas/mazdutide/ Mechanism: GLP-1/GCG. Route: s.c.. Company: Innovent (Lilly licence). Stage: approved. Status: Approved in China: obesity (June 2025) and T2D (September 2025); 9 mg supplementary NDA accepted (Nov 2025); GLORY-2 published (JAMA 2026). Next: 9 mg approval; GLORY-3 vs semaglutide. Indications: Obesity: 4 (approved / in label) — NMPA (China), June 2025; T2D: 4 (approved / in label) — NMPA (China), September 2025; CV outcomes: 2 (phase 3 ongoing) — Phase 3 ongoing; CKD: 2 (phase 3 ongoing) — Phase 3 ongoing; HFpEF: 1 (phase 2 / signal) — Phase 2 only; MASH: 2 (phase 3 ongoing) — Phase 3 ongoing; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 ongoing; Knee OA: 0 (no data) — ; Alzheimer's: 2 (phase 3 ongoing) — Phase 3 in T2D with early cognitive impairment ongoing - US phase 2 (NCT06124807): 3-6 mg (3 mg to week 32) | pop obesity | 32 wk | n=179 | weight eff -7.3 vs -0.9 % | status press | src Eli Lilly. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based phase 2 trial, Lancet Diabetes Endocrinol 2026 [publication]. 2026-08-21 https://pubmed.ncbi.nlm.nih.gov/42628555/ - US phase 2 (NCT06124807): 10 mg | pop obesity | 32 wk | n=179 | weight eff -15.6 vs -0.9 % | status press | src Eli Lilly. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based phase 2 trial, Lancet Diabetes Endocrinol 2026 [publication]. 2026-08-21 https://pubmed.ncbi.nlm.nih.gov/42628555/ - US phase 2 (NCT06124807): 16 mg | pop obesity | 32 wk | n=179 | weight eff -18.1 vs -0.9 % | AE d/c % 20 vs None | status press | src Eli Lilly. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based phase 2 trial, Lancet Diabetes Endocrinol 2026 [publication]. 2026-08-21 https://pubmed.ncbi.nlm.nih.gov/42628555/ - DREAMS-1: 4 mg | pop t2d | 24 wk | n=320 | weight tp -5.5 vs -1.15 % | HbA1c pp -1.58 vs -0.25 | status press | src Innovent. Nature: Two Phase 3 Clinical Results of Mazdutide in Chinese Adults with Type 2 Diabetes Published Back-to-back (DREAMS-1, DREAMS-2) [press release]. 2025-12-17 https://www.prnewswire.com/news-releases/nature--two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature-302644606.html - DREAMS-1: 6 mg | pop t2d | 24 wk | n=320 | weight tp -7.34 vs -1.15 % | HbA1c pp -2.02 vs -0.25 | status press | src Innovent. Nature: Two Phase 3 Clinical Results of Mazdutide in Chinese Adults with Type 2 Diabetes Published Back-to-back (DREAMS-1, DREAMS-2) [press release]. 2025-12-17 https://www.prnewswire.com/news-releases/nature--two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature-302644606.html - DREAMS-3: 6 mg | pop t2d | 32 wk | n=349 | weight (estimand n/s) -10.29 vs None % | HbA1c pp -2.03 vs None | status press | src Innovent. Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 [press release]. 2025-10-26 https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html - GLORY-1: mazdutide 4 mg | pop obesity | 48 wk | n=None | weight tp -11.0 vs 0.3 % | AE d/c % 1.5 vs 1.0 | any d/c % 11.3 vs 5.4 | nausea % 32.5 vs 5.9 | vomiting % 26.1 vs 2.9 | SAE % 5.9 vs 6.3 | status verified-2 | src GLORY-1, N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40421736/ - GLORY-1: mazdutide 6 mg | pop obesity | 48 wk | n=None | weight tp -14.01 vs 0.3 % | AE d/c % 0.5 vs 1.0 | any d/c % 10.9 vs 5.4 | nausea % 50.5 vs 5.9 | vomiting % 43.1 vs 2.9 | SAE % 4.0 vs 6.3 | status verified-2 | src GLORY-1, N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40421736/ - GLORY-2: mazdutide 9 mg | pop obesity | 60 wk | n=None | weight eff -18.55 vs -3.02 % | weight tp -16.65 vs -1.5 % | AE d/c % 2.9 vs 0 | any d/c % 13.0 vs 5.2 | nausea % 46.9 vs 3.2 | vomiting % 53.1 vs 1.3 | SAE % 7.2 vs 5.2 | SBP mmHg -9.8 vs -0.23 | status verified-2 | src GLORY-2, JAMA 2026 https://pubmed.ncbi.nlm.nih.gov/42251595/ - DREAMS-2: mazdutide 4 mg | pop t2d | 28 wk | n=None | weight tp -6.55 vs None % | HbA1c pp -1.61 vs None | AE d/c % 2.1 vs None | any d/c % 8.7 vs None | nausea % 35.5 vs None | vomiting % 24.0 vs None | SAE % 5.8 vs None | status verified-2 | src DREAMS-2, Nature 2026 https://pubmed.ncbi.nlm.nih.gov/41407860/ - DREAMS-2: mazdutide 6 mg | pop t2d | 28 wk | n=None | weight tp -8.53 vs None % | HbA1c pp -1.66 vs None | AE d/c % 3.7 vs None | any d/c % 13.1 vs None | nausea % 34.4 vs None | vomiting % 29.1 vs None | SAE % 4.9 vs None | status verified-2 | src DREAMS-2, Nature 2026 https://pubmed.ncbi.nlm.nih.gov/41407860/ ### MariTide (maridebart cafraglutide) — https://docs.mdwrt.app/infographics/incretin-atlas/maritide/ Mechanism: GLP-1 + GIPR antagonist (antibody). Route: s.c. monthly. Company: Amgen. Stage: phase 3. Status: Phase 3 (MARITIME). Next: MARITIME-1/-2 readouts 2027. Indications: Obesity: 2 (phase 3 ongoing) — MARITIME phase 3 programme ongoing; T2D: 2 (phase 3 ongoing) — Phase 3 ongoing; CV outcomes: 2 (phase 3 ongoing) — Phase 3 ongoing; CKD: 0 (no data) — ; HFpEF: 2 (phase 3 ongoing) — Phase 3 ongoing; MASH: 0 (no data) — ; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 ongoing; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - MariTide phase 2 (obesity cohort): MariTide 140 mg every 4 weeks (no escalation) | pop obesity | 52 wk | n=77 | weight eff -16.3 vs -2.6 % | weight tp -13.6 vs -2.5 % | AE d/c % 14.0 vs 1.0 | nausea % 77.0 vs 25.0 | vomiting % 68.0 vs 3.0 | SAE % 5.0 vs 7.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity cohort): MariTide 280 mg every 4 weeks (no escalation) | pop obesity | 52 wk | n=77 | weight eff -19.9 vs -2.6 % | weight tp -15.5 vs -2.5 % | AE d/c % 14.0 vs 1.0 | nausea % 78.0 vs 25.0 | vomiting % 73.0 vs 3.0 | SAE % 5.0 vs 7.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity cohort): MariTide 420 mg every 4 weeks (no escalation) | pop obesity | 52 wk | n=79 | weight eff -18.9 vs -2.6 % | weight tp -14.6 vs -2.5 % | AE d/c % 22.0 vs 1.0 | nausea % 87.0 vs 25.0 | vomiting % 87.0 vs 3.0 | SAE % 6.0 vs 7.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity cohort): MariTide 420 mg every 8 weeks (no escalation) | pop obesity | 52 wk | n=51 | weight eff -17.7 vs -2.6 % | weight tp -12.3 vs -2.5 % | AE d/c % 29.0 vs 1.0 | nausea % 82.0 vs 25.0 | vomiting % 92.0 vs 3.0 | SAE % 14.0 vs 7.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity cohort): MariTide 420 mg every 4 weeks, 4-week dose escalation | pop obesity | 52 wk | n=51 | weight eff -16.7 vs -2.6 % | weight tp -14.1 vs -2.5 % | AE d/c % 10.0 vs 1.0 | nausea % 71.0 vs 25.0 | vomiting % 43.0 vs 3.0 | SAE % 0.0 vs 7.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity cohort): MariTide 420 mg every 4 weeks, 12-week dose escalation | pop obesity | 52 wk | n=52 | weight eff -19.9 vs -2.6 % | weight tp -16.2 vs -2.5 % | AE d/c % 12.0 vs 1.0 | nausea % 73.0 vs 25.0 | vomiting % 44.0 vs 3.0 | SAE % 6.0 vs 7.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity with T2D cohort): MariTide 140 mg every 4 weeks (no escalation) | pop t2d | 52 wk | n=31 | weight eff -12.3 vs -1.4 % | weight tp -10.3 vs -1.7 % | HbA1c pp -1.6 vs 0.1 | AE d/c % 13.0 vs 3.0 | nausea % 58.0 vs 9.0 | vomiting % 45.0 vs 6.0 | SAE % 3.0 vs 0.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity with T2D cohort): MariTide 280 mg every 4 weeks (no escalation) | pop t2d | 52 wk | n=32 | weight eff -12.1 vs -1.4 % | weight tp -8.4 vs -1.7 % | HbA1c pp -1.2 vs 0.1 | AE d/c % 19.0 vs 3.0 | nausea % 41.0 vs 9.0 | vomiting % 50.0 vs 6.0 | SAE % 6.0 vs 0.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 - MariTide phase 2 (obesity with T2D cohort): MariTide 420 mg every 4 weeks (no escalation) | pop t2d | 52 wk | n=32 | weight eff -17.0 vs -1.4 % | weight tp -12.3 vs -1.7 % | HbA1c pp -1.5 vs 0.1 | AE d/c % 16.0 vs 3.0 | nausea % 59.0 vs 9.0 | vomiting % 75.0 vs 6.0 | SAE % 12.0 vs 0.0 | status verified-2 | src Jastreboff AM et al. N Engl J Med 2025 https://pubmed.ncbi.nlm.nih.gov/40549887/; NCT05669599 https://clinicaltrials.gov/study/NCT05669599 ### Amycretin (zenagamtide) — https://docs.mdwrt.app/infographics/incretin-atlas/amycretin/ Mechanism: GLP-1 + amylin (unimolecular). Route: s.c. / oral. Company: Novo Nordisk. Stage: phase 3. Status: Phase 3 (AMAZE) started. Next: Phase 3 of the oral form. Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 (AMAZE) ongoing; T2D: 2 (phase 3 ongoing) — Phase 2 positive (Lancet 2026); phase 3 ongoing; CV outcomes: 2 (phase 3 ongoing) — Phase 3 ongoing; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - Amycretin s.c. phase 1b/2a: amycretin 60 mg | pop obesity | 36 wk | n=125 | weight eff -24.3 vs -1.1 % | HbA1c pp -0.6 vs -0.1 | nausea % 82.0 vs 60.0 | vomiting % 47.0 vs 60.0 | SAE % 0.0 vs 0.0 | status verified-2 | src PubMed: amycretin s.c. (Lancet 2025) https://pubmed.ncbi.nlm.nih.gov/?term=amycretin+subcutaneous+obesity - Amycretin s.c. phase 1b/2a: amycretin 20 mg | pop obesity | 36 wk | n=125 | weight eff -22.0 vs 2.0 % | HbA1c pp -0.3 vs -0.1 | nausea % 79.0 vs 40.0 | vomiting % 53.0 vs 20.0 | SAE % 3.0 vs 0.0 | status verified-2 | src PubMed: amycretin s.c. (Lancet 2025) https://pubmed.ncbi.nlm.nih.gov/?term=amycretin+subcutaneous+obesity - Amycretin oral phase 1: oral amycretin 50 mg | pop obesity | 12 wk | n=144 | weight (estimand n/s) -10.4 vs -1.2 % | HbA1c pp -0.2 vs 0.0 | nausea % 31 vs 8 | vomiting % 38 vs 0 | SAE % 0 vs 0 | status verified-2 | src PubMed: oral amycretin (Lancet 2025) https://pubmed.ncbi.nlm.nih.gov/?term=amycretin+oral+phase+1 - Zenagamtide s.c. phase 2 (T2D): zenagamtide 10 mg weekly | pop t2d | 36 wk | n=38 | weight eff -12.9 vs -2.1 % | HbA1c pp -1.4 vs -0.1 | AE d/c % 21.0 vs 6.0 | nausea % 26.0 vs 14.0 | vomiting % 11.0 vs 6.0 | SAE % 13.0 vs 8.0 | SBP mmHg -9.4 vs -3.5 | status verified-2 | src Zenagamtide s.c. phase 2, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42532080/ - Zenagamtide s.c. phase 2 (T2D): zenagamtide 20 mg weekly | pop t2d | 36 wk | n=38 | weight eff -13.1 vs -2.1 % | HbA1c pp -1.6 vs -0.1 | AE d/c % 34.0 vs 6.0 | any d/c % 45.0 vs 14.0 | nausea % 50.0 vs 14.0 | vomiting % 24.0 vs 6.0 | SAE % 8.0 vs 8.0 | SBP mmHg -7.2 vs -3.5 | status verified-2 | src Zenagamtide s.c. phase 2, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42532080/ - Zenagamtide s.c. phase 2 (T2D): zenagamtide 40 mg weekly | pop t2d | 36 wk | n=38 | weight eff -14.6 vs -2.1 % | HbA1c pp -1.7 vs -0.1 | AE d/c % 34.0 vs 6.0 | any d/c % 45.0 vs 14.0 | nausea % 37.0 vs 14.0 | vomiting % 29.0 vs 6.0 | SAE % 3.0 vs 8.0 | SBP mmHg -10.6 vs -3.5 | status verified-2 | src Zenagamtide s.c. phase 2, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42532080/ ### Eloralintide (LY3841136) — https://docs.mdwrt.app/infographics/incretin-atlas/eloralintide/ Mechanism: Amylin. Route: s.c.. Company: Eli Lilly. Stage: phase 3. Status: Phase 3 ENLIGHTEN programme recruiting since Dec 2025 (obesity, T2D, sleep apnoea, knee osteoarthritis, maintenance after incretin therapy); phase 2 complete. Next: ENLIGHTEN phase 3 results. Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 ongoing; T2D: 2 (phase 3 ongoing) — Phase 3 ongoing; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 ongoing; Knee OA: 2 (phase 3 ongoing) — Phase 3 ongoing; Alzheimer's: 0 (no data) — - EloraTZP phase 2b (obesity + T2D): eloralintide 3 mg | pop t2d | 48 wk | n=None | weight eff -8.2 vs -3.0 % | HbA1c pp -1.1 vs -0.3 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html - EloraTZP phase 2b (obesity + T2D): eloralintide 6 mg | pop t2d | 48 wk | n=None | weight eff -12.3 vs -3.0 % | HbA1c pp -1.4 vs -0.3 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html - EloraTZP phase 2b (obesity + T2D): eloralintide 9 mg | pop t2d | 48 wk | n=None | weight eff -11.1 vs -3.0 % | HbA1c pp -1.3 vs -0.3 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html ### Petrelintide (ZP8396) — https://docs.mdwrt.app/infographics/incretin-atlas/petrelintide/ Mechanism: Amylin. Route: s.c.. Company: Zealand / Roche. Stage: phase 3. Status: Phase 3 ZUPREME programme (ZUPREME-3, -4, -5) initiated with Roche; phase 2 ZUPREME-1 published (Lancet Diabetes Endocrinol 2026), ZUPREME-2 topline in T2D (Oct 2026). Next: Phase 3 readouts. Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 ongoing; T2D: 2 (phase 3 ongoing) — Phase 3 ongoing; CV outcomes: 2 (phase 3 ongoing) — Phase 3 ongoing; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - ZUPREME-1: petrelintide 1.0 mg | pop obesity | 28 wk | n=None | weight eff -7.9 vs -1.7 % | AE d/c % 5 vs 5 | any d/c % 16.5 vs 24.7 | nausea % 19 vs 6 | vomiting % 4 vs 6 | SAE % 3 vs 4 | status verified-2 | src ZUPREME-1, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42810355/ - ZUPREME-1: petrelintide 2.5 mg | pop obesity | 28 wk | n=None | weight eff -7.9 vs -1.7 % | AE d/c % 1 vs 5 | any d/c % 11.1 vs 24.7 | nausea % 12 vs 6 | vomiting % 0 vs 6 | SAE % 1 vs 4 | status verified-2 | src ZUPREME-1, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42810355/ - ZUPREME-1: petrelintide 5.0 mg | pop obesity | 28 wk | n=None | weight eff -9.8 vs -1.7 % | AE d/c % 5 vs 5 | any d/c % 9.6 vs 24.7 | nausea % 23 vs 6 | vomiting % 0 vs 6 | SAE % 6 vs 4 | status verified-2 | src ZUPREME-1, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42810355/ - ZUPREME-1: petrelintide 7.0 mg | pop obesity | 28 wk | n=None | weight eff -9.3 vs -1.7 % | AE d/c % 1 vs 5 | any d/c % 12.7 vs 24.7 | nausea % 15 vs 6 | vomiting % 3 vs 6 | SAE % 4 vs 4 | status verified-2 | src ZUPREME-1, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42810355/ - ZUPREME-1: petrelintide 9.0 mg | pop obesity | 28 wk | n=None | weight eff -9.4 vs -1.7 % | AE d/c % 10 vs 5 | any d/c % 18.3 vs 24.7 | nausea % 28 vs 6 | vomiting % 9 vs 6 | SAE % 4 vs 4 | status verified-2 | src ZUPREME-1, Lancet Diabetes Endocrinol 2026 https://pubmed.ncbi.nlm.nih.gov/42810355/ - ZUPREME-2 (obesity + T2D): petrelintide, highest dose | pop t2d | 28 wk | n=None | weight eff -9.2 vs -2.0 % | HbA1c pp -0.65 vs 0.23 | status press | src Zealand Pharma. Positive phase 2 ZUPREME-2 topline results for petrelintide [company announcement No. 54/2026]. 2026 Oct 7 https://view.news.eu.nasdaq.com/view?id=1468986 ### CT-388 (Roche / Carmot) — https://docs.mdwrt.app/infographics/incretin-atlas/ct-388/ Mechanism: GIP/GLP-1. Route: s.c.. Company: Roche. Stage: phase 3. Status: Phase 3 (Enith1, Enith2 and a third trial) recruiting since Mar 2026; phase 2 (48 weeks) presented at EASD 2026. Next: Phase 3 results (primary completion 2028). - CT-388 phase 2: CT-388 24 mg | pop obesity | 48 wk | n=None | weight eff -22.7 vs -0.2 % | status verified-2 | src EASD 2026, abstract 64054 https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - CT-388-104 (T2D): enicepatide 24 mg | pop t2d | 48 wk | n=None | weight (estimand n/s) -15.5 vs None % | HbA1c pp -2.65 vs None | status press | src Roche. Enicepatide phase II results in type 2 diabetes with overweight or obesity [ad hoc announcement]. 2026 Sep 22 https://www.roche.com/media/releases/med-cor-2026-09-22 ### Pemvidutide (ALT-801) — https://docs.mdwrt.app/infographics/incretin-atlas/pemvidutide/ Mechanism: GLP-1/GCG. Route: s.c.. Company: Altimmune. Stage: phase 3. Status: Phase 3 PERFORMA in MASH recruiting since Jul 2026; phase 2 MOMENTUM (obesity) and IMPACT (MASH) complete. Next: PERFORMA results (primary completion Dec 2028). Indications: Obesity: 1 (phase 2 / signal) — Phase 2 (MOMENTUM); T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 2 (phase 3 ongoing) — Phase 2b IMPACT: MASH resolution met, fibrosis improvement not met at 24 weeks (Lancet 2025); phase 3 PERFORMA recruiting; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - MOMENTUM: pemvidutide 2.4 mg | pop obesity | 48 wk | n=391 | weight (estimand n/s) -15.6 vs -2.2 % | AE d/c % 19.6 vs 6.2 | nausea % 51.5 vs 11.3 | vomiting % 27.8 vs 3.1 | SBP mmHg -4.6 vs 3.5 | status press | src NCT05295875 https://clinicaltrials.gov/study/NCT05295875; Altimmune, Inc. Altimmune announces positive topline results from MOMENTUM 48-week phase 2 obesity trial of pemvidutide [press release, Form 8-K Exhibit 99.1]. Gaithersburg (MD): Altimmune; 2023 Nov 30. Available from: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130xex99d1.htm https://www.sec.gov/Archives/edgar/data/1326190/000132619023000050/alt-20231130xex99d1.htm - IMPACT (MASH F2–F3, n=212, 24 wk): MASH resolution without worsening of fibrosis +38 / +32 percentage points vs placebo at 24 weeks (1.2 / 1.8 mg); fibrosis improvement +5 / +8, not significant. At 48 weeks (no biopsy): liver fat −37.1 / −46.5 percentage points vs placebo. | status abstract | src https://pubmed.ncbi.nlm.nih.gov/41237796/; https://pubmed.ncbi.nlm.nih.gov/43014327/; https://clinicaltrials.gov/study/NCT05989711 ### Ecnoglutide (XW003) — https://docs.mdwrt.app/infographics/incretin-atlas/ecnoglutide/ Mechanism: GLP-1 (biased agonist). Route: s.c.. Company: Sciwind. Stage: approved. Status: Approved in China: T2D (January 2026) and weight management (March 2026); SLIMMER published (Lancet Diabetes Endocrinol 2025). Next: Global development (Verdiva/Pfizer licence for oral). Indications: Obesity: 4 (approved / in label) — NMPA (China), weight management, March 2026; T2D: 4 (approved / in label) — NMPA (China), January 2026; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 ongoing; Knee OA: 2 (phase 3 ongoing) — Phase 3 ongoing; Alzheimer's: 0 (no data) — - EECOH-1 (T2D monotherapy): ecnoglutide 1.2 mg | pop t2d | 24 wk | n=71 | weight tp -4.74 vs -2.02 % | HbA1c pp -2.43 vs -0.87 | AE d/c % 1.4 vs 1.4 | any d/c % 5.6 vs 2.8 | nausea % 12.7 vs 9.9 | SAE % 4.2 vs 5.6 | SBP mmHg -5.2 vs -2.1 | status verified-2 | src EECOH-1, 2026 https://pubmed.ncbi.nlm.nih.gov/41501026/ - SLIMMER: 1.2 mg | pop obesity | 48 wk | n=664 | weight tp -9.9 vs -0.3 % | status press | src Sciwind. Sciwind Biosciences Announces Publication of Phase III SLIMMER Trial Results in The Lancet Diabetes & Endocrinology (BioPharma Dive mirror of company release) [press release]. 2025-06-21 https://www.biopharmadive.com/press-release/20250621-sciwind-biosciences-announces-publication-of-phase-iii-slimmer-trial-result-1 - SLIMMER: 1.8 mg | pop obesity | 48 wk | n=664 | weight tp -13.3 vs -0.3 % | status press | src Sciwind. Sciwind Biosciences Announces Publication of Phase III SLIMMER Trial Results in The Lancet Diabetes & Endocrinology (BioPharma Dive mirror of company release) [press release]. 2025-06-21 https://www.biopharmadive.com/press-release/20250621-sciwind-biosciences-announces-publication-of-phase-iii-slimmer-trial-result-1 - SLIMMER: 2.4 mg | pop obesity | 48 wk | n=664 | weight tp -15.4 vs -0.3 % | status press | src Sciwind. Sciwind Biosciences Announces Publication of Phase III SLIMMER Trial Results in The Lancet Diabetes & Endocrinology (BioPharma Dive mirror of company release) [press release]. 2025-06-21 https://www.biopharmadive.com/press-release/20250621-sciwind-biosciences-announces-publication-of-phase-iii-slimmer-trial-result-1 - SLIMMER-UP-SWITCH (interim): 2.4 mg | pop obesity | 20 wk | n=163 | weight (estimand n/s) -12.8 vs None % | status press | src Sciwind. Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide (BioSpace mirror) [press release]. 2026-06-07 https://www.biospace.com/press-releases/head-to-head-study-validates-the-clinical-advantage-of-new-generation-biased-glp-1-ecnoglutide-delivers-35-greater-weight-loss-than-semaglutide - EECOH-1: 0.6 mg | pop t2d | 24 wk | n=211 | weight (estimand n/s) -4.51 vs -2.02 % | HbA1c pp -1.96 vs -0.87 | AE d/c % 1.4 vs 1.4 | any d/c % 4.3 vs 2.8 | nausea % 7.2 vs 9.9 | SAE % 2.9 vs 5.6 | status press | src Sciwind. Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003) in Adult Patients with Type 2 Diabetes in China [press release]. 2024-01-02 https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-topline-results-from-phase-3-clinical-trial-of-ecnoglutide-xw003-a-long-acting-camp-signaling-biased-glp-1-analog-in-adult-patients-with-type-2-diabetes-in-china-302023591.html - EECOH-2: 0.6 mg | pop t2d | 32 wk | n=623 | HbA1c pp -1.91 vs None | AE d/c % 3 vs None | status press | src Sciwind. Ecnoglutide versus dulaglutide in type 2 diabetes on metformin (EECOH-2), Lancet Diabetes Endocrinol 2025 [publication]. 2025-08-22 https://pubmed.ncbi.nlm.nih.gov/40854315/ - EECOH-2: 1.2 mg | pop t2d | 32 wk | n=623 | HbA1c pp -1.89 vs None | AE d/c % 4 vs None | status press | src Sciwind. Ecnoglutide versus dulaglutide in type 2 diabetes on metformin (EECOH-2), Lancet Diabetes Endocrinol 2025 [publication]. 2025-08-22 https://pubmed.ncbi.nlm.nih.gov/40854315/ ### Ribupatide (HRS9531) (KAI-9531, Hengrui / Kailera) — https://docs.mdwrt.app/infographics/incretin-atlas/ribupatide/ Mechanism: GIP/GLP-1. Route: s.c.. Company: Hengrui / Kailera. Stage: filed. Status: Phase 3 positive in China (GEMINI-1: −17.7 % TP / −19.2 % at 48 weeks); NDA accepted in China (Sep 2025); global phase 3 KaiNETIC enrolled (Kailera). Next: China approval; KaiNETIC topline mid-2028. Indications: Obesity: 3 (positive phase 3) — Positive phase 3 in China (GEMINI-1); NDA accepted Sep 2025; T2D: 3 (positive phase 3) — Positive phase 3 versus semaglutide (HbA1c −2.78 vs −2.29 %); CV outcomes: 2 (phase 3 ongoing) — Phase 3 ongoing; CKD: 0 (no data) — ; HFpEF: 1 (phase 2 / signal) — Phase 2 only; MASH: 1 (phase 2 / signal) — Phase 2 only; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 ongoing; Knee OA: 2 (phase 3 ongoing) — Phase 3 ongoing; Alzheimer's: 0 (no data) — - Ribupatide phase 2 (obesity + PMOS): ribupatide 4 mg | pop obesity | 32 wk | n=158 | weight tp -20.2 vs -2.6 % | AE d/c % 0.0 vs 0.0 | SAE % 0.0 vs 0.0 | status verified-2 | src EASD 2026, abstract LBA 74 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/; EASD 2026 LBA 74: Ribupatide (HRS9531) in obesity and PMOS, phase 2 (NCT06595797). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - Ribupatide phase 2 (obesity + PMOS): ribupatide 2 mg | pop obesity | 32 wk | n=158 | weight tp -15.1 vs -2.6 % | AE d/c % 0.0 vs 0.0 | SAE % 0.0 vs 0.0 | status verified-2 | src EASD 2026, abstract LBA 74 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/; EASD 2026 LBA 74: Ribupatide (HRS9531) in obesity and PMOS, phase 2 (NCT06595797). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - HRS9531-301 (GEMINI-1, NCT06396429): 2 mg | pop obesity | 48 wk | n=567 | weight eff -11.2 vs -1.4 % | weight tp -10.7 vs -1.4 % | AE d/c % 0.7 vs 0 | nausea % 16.2 vs 4.9 | vomiting % 14.1 vs 2.1 | SAE % 1.4 vs 5.6 | status press | src Hengrui / Kailera. Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 (GlobeNewswire text mirrored by santelog.com) [press release]. 2025-11-04 https://www.santelog.com/actualites-sante-nasdaq/hengrui-pharma-and-kailera-therapeutics-announce-additional-data-phase-3; Efficacy and Safety of HRS9531 in Chinese Adults Living with Overweight or Obesity Without Diabetes (HRS9531-301), ObesityWeek 2025 presentation. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://www.kailera.com/wp-content/uploads/2025/11/Hengrui_ObesityWeek-2025_HRS9531_Phase_3_Clinical_Trial_Results.pdf - HRS9531-301 (GEMINI-1, NCT06396429): 4 mg | pop obesity | 48 wk | n=567 | weight eff -17.4 vs -1.4 % | weight tp -16.4 vs -1.4 % | AE d/c % 0.7 vs 0 | nausea % 17.0 vs 4.9 | vomiting % 19.1 vs 2.1 | SAE % 5.0 vs 5.6 | status press | src Hengrui / Kailera. Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 (GlobeNewswire text mirrored by santelog.com) [press release]. 2025-11-04 https://www.santelog.com/actualites-sante-nasdaq/hengrui-pharma-and-kailera-therapeutics-announce-additional-data-phase-3; Efficacy and Safety of HRS9531 in Chinese Adults Living with Overweight or Obesity Without Diabetes (HRS9531-301), ObesityWeek 2025 presentation. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://www.kailera.com/wp-content/uploads/2025/11/Hengrui_ObesityWeek-2025_HRS9531_Phase_3_Clinical_Trial_Results.pdf - HRS9531-301 (GEMINI-1, NCT06396429): 6 mg | pop obesity | 48 wk | n=567 | weight eff -19.2 vs -1.4 % | weight tp -17.7 vs -1.4 % | AE d/c % 1.4 vs 0 | nausea % 27.0 vs 4.9 | vomiting % 24.1 vs 2.1 | SAE % 4.3 vs 5.6 | status press | src Hengrui / Kailera. Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 (GlobeNewswire text mirrored by santelog.com) [press release]. 2025-11-04 https://www.santelog.com/actualites-sante-nasdaq/hengrui-pharma-and-kailera-therapeutics-announce-additional-data-phase-3; Efficacy and Safety of HRS9531 in Chinese Adults Living with Overweight or Obesity Without Diabetes (HRS9531-301), ObesityWeek 2025 presentation. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://www.kailera.com/wp-content/uploads/2025/11/Hengrui_ObesityWeek-2025_HRS9531_Phase_3_Clinical_Trial_Results.pdf - HRS9531-203 (NCT06054698): 8 mg | pop obesity | 36 wk | n=None | weight eff -23.6 vs None % | weight tp -22.8 vs None % | status press | src Hengrui / Kailera. Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 (GlobeNewswire via BioSpace) [press release]. 2025-07-15 https://www.biospace.com/press-releases/hengrui-pharma-and-kailera-therapeutics-report-positive-topline-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1-gip-receptor-agonist-hrs9531 - HRS9531-201 (NCT05881837): 1.0 mg | pop obesity | 24 wk | n=249 | weight tp -5.4 vs -0.1 % | AE d/c % 2.0 vs 2.0 | nausea % 14.3 vs 8.2 | vomiting % 6.1 vs 2.0 | status easd | src HRS9531-201 phase 2 obesity poster, ADA 2024. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://kailera.com/wp-content/uploads/2024/09/HRS9531-201_ADA2024_Poster.pdf - HRS9531-201 (NCT05881837): 3.0 mg | pop obesity | 24 wk | n=249 | weight tp -13.4 vs -0.1 % | AE d/c % 2.0 vs 2.0 | nausea % 27.5 vs 8.2 | vomiting % 19.6 vs 2.0 | status easd | src HRS9531-201 phase 2 obesity poster, ADA 2024. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://kailera.com/wp-content/uploads/2024/09/HRS9531-201_ADA2024_Poster.pdf - HRS9531-201 (NCT05881837): 4.5 mg | pop obesity | 24 wk | n=249 | weight tp -14.0 vs -0.1 % | AE d/c % 0 vs 2.0 | nausea % 32.0 vs 8.2 | vomiting % 20.0 vs 2.0 | status easd | src HRS9531-201 phase 2 obesity poster, ADA 2024. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://kailera.com/wp-content/uploads/2024/09/HRS9531-201_ADA2024_Poster.pdf - HRS9531-201 (NCT05881837): 6.0 mg | pop obesity | 24 wk | n=249 | weight tp -16.8 vs -0.1 % | AE d/c % 0 vs 2.0 | nausea % 32.7 vs 8.2 | vomiting % 28.6 vs 2.0 | status easd | src HRS9531-201 phase 2 obesity poster, ADA 2024. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://kailera.com/wp-content/uploads/2024/09/HRS9531-201_ADA2024_Poster.pdf - HRS9531-T-201 oral ribupatide (NCT06841445): 10 mg oral QD | pop obesity | 26 wk | n=166 | weight eff -6.9 vs -2.3 % | weight tp -6.7 vs -2.1 % | AE d/c % 0 vs 0 | nausea % 11.9 vs 7.5 | vomiting % 2.4 vs 0 | SAE % 2.4 vs 2.5 | SBP mmHg -6.1 vs -3.9 | status press | src Efficacy and Safety of Oral Ribupatide (HRS9531) in Chinese Adults with Obesity: A Phase 2 Trial, ADA 2026 poster 2816-LB. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://www.kailera.com/wp-content/uploads/2026/06/HRS9531-T-201_ADA-2026_poster_22May.pdf; Kailera / Hengrui. Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide (GlobeNewswire via BioSpace) [press release]. 2026-02-10 https://www.biospace.com/press-releases/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide - HRS9531-T-201 oral ribupatide (NCT06841445): 25 mg oral QD | pop obesity | 26 wk | n=166 | weight eff -12.1 vs -2.3 % | weight tp -11.9 vs -2.1 % | AE d/c % 0 vs 0 | nausea % 22.7 vs 7.5 | vomiting % 11.4 vs 0 | SAE % 4.5 vs 2.5 | SBP mmHg -6.4 vs -3.9 | status press | src Efficacy and Safety of Oral Ribupatide (HRS9531) in Chinese Adults with Obesity: A Phase 2 Trial, ADA 2026 poster 2816-LB. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://www.kailera.com/wp-content/uploads/2026/06/HRS9531-T-201_ADA-2026_poster_22May.pdf; Kailera / Hengrui. Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide (GlobeNewswire via BioSpace) [press release]. 2026-02-10 https://www.biospace.com/press-releases/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide - HRS9531-T-201 oral ribupatide (NCT06841445): 50 mg oral QD | pop obesity | 26 wk | n=166 | weight eff -12.1 vs -2.3 % | weight tp -11.4 vs -2.1 % | AE d/c % 2.5 vs 0 | nausea % 20.0 vs 7.5 | vomiting % 7.5 vs 0 | SAE % 0 vs 2.5 | SBP mmHg -5.1 vs -3.9 | status press | src Efficacy and Safety of Oral Ribupatide (HRS9531) in Chinese Adults with Obesity: A Phase 2 Trial, ADA 2026 poster 2816-LB. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://www.kailera.com/wp-content/uploads/2026/06/HRS9531-T-201_ADA-2026_poster_22May.pdf; Kailera / Hengrui. Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide (GlobeNewswire via BioSpace) [press release]. 2026-02-10 https://www.biospace.com/press-releases/kailera-therapeutics-and-hengrui-pharma-report-positive-topline-data-from-phase-2-obesity-trial-of-oral-ribupatide - Ribupatide in obesity + PMOS (NCT06595797): 1 mg | pop obesity | 32 wk | n=158 | weight tp -10.0 vs -2.6 % | AE d/c % 0 vs 0 | SAE % 0 vs 0 | status easd | src EASD 2026 LBA 74: Ribupatide (HRS9531) in obesity and PMOS, phase 2 (NCT06595797). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344): 4 mg | pop t2d | 36 wk | n=None | HbA1c pp -2.78 vs None | status press | src Kailera. Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates (8-K Ex. 99.1) [press release]. 2026-08-12 https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm - Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344): 2 mg | pop t2d | 36 wk | n=None | HbA1c pp -2.34 vs None | status press | src Kailera. Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates (8-K Ex. 99.1) [press release]. 2026-08-12 https://www.sec.gov/Archives/edgar/data/2096997/000119312526346919/ck0002096997-ex99_1.htm ### UBT251 (United Laboratories) — https://docs.mdwrt.app/infographics/incretin-atlas/ubt251/ Mechanism: GIP/GLP-1/GCG. Route: s.c.. Company: United Laboratories (Novo Nordisk licence). Stage: phase 3. Status: Phase 3 in China: UNIGUIDE-1 (T2D) recruiting since Sep 2026; obesity and sleep apnoea trials registered; phase 2 (T2D) at EASD 2026. Next: Phase 3 results in China (primary completion from Sep 2027). Indications: Obesity: 2 (phase 3 ongoing) — Phase 2 positive (EASD 2026: up to −19.7 % at 24 weeks); phase 3 ongoing; T2D: 2 (phase 3 ongoing) — Phase 2 positive (Cell Metabolism, October 2026); phase 3 ongoing; CV outcomes: 0 (no data) — ; CKD: 1 (phase 2 / signal) — Phase 2 only; HFpEF: 0 (no data) — ; MASH: 1 (phase 2 / signal) — Phase 2 only; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - UBT251 phase 2 (obesity): UBT251 4.0 mg (start 1.0 mg) | pop obesity | 24 wk | n=None | weight (estimand n/s) -19.7 vs -2.0 % | status verified-2 | src EASD 2026, abstract 797 https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Zhou Z et al. Cell Metab 2026 https://pubmed.ncbi.nlm.nih.gov/42843337/ - UBT251 phase 2 (obesity): UBT251 6.0 mg | pop obesity | 24 wk | n=None | weight (estimand n/s) -18.7 vs -2.0 % | status verified-2 | src EASD 2026, abstract 797 https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Zhou Z et al. Cell Metab 2026 https://pubmed.ncbi.nlm.nih.gov/42843337/ - UBT251 phase 2 (obesity): UBT251 2.0 mg | pop obesity | 24 wk | n=None | weight (estimand n/s) -13.6 vs -2.0 % | status verified-2 | src EASD 2026, abstract 797 https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Zhou Z et al. Cell Metab 2026 https://pubmed.ncbi.nlm.nih.gov/42843337/ - UBT251 phase 2 (T2D): UBT251 2.0 mg | pop t2d | 24 wk | n=None | HbA1c pp -2.16 vs -0.66 | status verified-2 | src Zhou Z et al. Cell Metab 2026 (UBT251 phase 2, type 2 diabetes) https://pubmed.ncbi.nlm.nih.gov/42933400/; EASD 2026, abstract 124 https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - UBT251 phase 2 (T2D): UBT251 6.0 mg | pop t2d | 24 wk | n=None | HbA1c pp -2.08 vs -0.66 | status verified-2 | src Zhou Z et al. Cell Metab 2026 (UBT251 phase 2, type 2 diabetes) https://pubmed.ncbi.nlm.nih.gov/42933400/; EASD 2026, abstract 124 https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - UBT251 phase 2 obesity China (NCT07177469): 4.0 mg (initial dose 0.5 mg) | pop obesity | 24 wk | n=205 | weight (estimand n/s) -16.2 vs -2.0 % | status easd | src EASD 2026 abstract: UBT251 in overweight/obesity, phase 2 (NCT07177469). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Zhou Z et al. Cell Metab 2026 https://pubmed.ncbi.nlm.nih.gov/42843337/ - UBT251 phase 2 T2D China (NCT07163624): 4.0 mg (initial dose 0.5 mg) | pop t2d | 24 wk | n=211 | HbA1c pp -1.98 vs -0.66 | status easd | src Zhou Z et al. Cell Metab 2026 (UBT251 phase 2, type 2 diabetes) https://pubmed.ncbi.nlm.nih.gov/42933400/; EASD 2026 abstract: UBT251 in T2D, phase 2 (NCT07163624). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - UBT251 phase 2 T2D China (NCT07163624): 4.0 mg (initial dose 1.0 mg) | pop t2d | 24 wk | n=211 | HbA1c pp -2.08 vs -0.66 | status easd | src Zhou Z et al. Cell Metab 2026 (UBT251 phase 2, type 2 diabetes) https://pubmed.ncbi.nlm.nih.gov/42933400/; EASD 2026 abstract: UBT251 in T2D, phase 2 (NCT07163624). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ ### Efinopegdutide (MK-6024) — https://docs.mdwrt.app/infographics/incretin-atlas/efinopegdutide/ Mechanism: GLP-1/GCG. Route: s.c.. Company: MSD (Hanmi). Stage: phase 2. Status: Phase 2b MASH. Next: Phase 3 MASH. Indications: Obesity: 0 (no data) — ; T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 1 (phase 2 / signal) — Positive phase 2b (Lancet, Nov 2026); Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - Phase 2b (MASH F2–F3, n=386, 52 wk): MASH resolution without worsening of fibrosis +43.0 / +49.5 / +47.8 percentage points vs placebo (4 / 7 / 10 mg); fibrosis improvement +21.7 / +30.4 / +13.0 (10 mg not significant). Open-label semaglutide 2.4 mg arm: 53 % and 25 %. | status abstract | src https://pubmed.ncbi.nlm.nih.gov/43003105/; https://clinicaltrials.gov/study/NCT05877547 ### RGT-075 (Regor) — https://docs.mdwrt.app/infographics/incretin-atlas/rgt-075/ Mechanism: GLP-1 (small molecule). Route: oral. Company: Regor. Stage: phase 2. Status: Phase 2b (36 weeks) presented at EASD 2026. Next: Phase 3. - RGT-075 phase 2b: RGT-075 180 mg oral | pop obesity | 36 wk | n=None | weight eff -10.4 vs -1.6 % | weight tp -10.4 vs -1.6 % | SBP mmHg -9.9 vs 0.0 | status verified-2 | src EASD 2026, abstract 63853 https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ ### HRS-7535 (Hengrui) — https://docs.mdwrt.app/infographics/incretin-atlas/hrs-7535/ Mechanism: GLP-1 (small molecule). Route: oral. Company: Hengrui. Stage: filed. Status: Phase 3 positive: OUTSTAND-1/-2 (T2D), HARBOR-1 (obesity); NDAs accepted in China for T2D and weight management (Sep 2026). Next: China approval. Indications: Obesity: 3 (positive phase 3) — Positive phase 3 HARBOR-1; NDA accepted Sep 2026; T2D: 3 (positive phase 3) — Positive phase 3 OUTSTAND-1/-2; NDA accepted Sep 2026; CV outcomes: 0 (no data) — ; CKD: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; HFpEF: 1 (phase 2 / signal) — Phase 2 only; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - OUTSTAND-1 (early T2D, monotherapy): oral HRS-7535 90 mg | pop t2d | 32 wk | n=284 | HbA1c pp -1.68 vs -0.06 | AE d/c % 6.9 vs 0 | status easd | src EASD 2026, abstract LBA 39 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/; EASD 2026 LBA 39: HRS-7535 monotherapy, OUTSTAND-1 phase 3 (NCT06672172). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07 https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535 - OUTSTAND-1 (HRS-7535-301, NCT06672172): 30 mg | pop t2d | 32 wk | n=284 | HbA1c pp -1.4 vs -0.18 | AE d/c % 1.4 vs 0 | status easd | src EASD 2026 LBA 39: HRS-7535 monotherapy, OUTSTAND-1 phase 3 (NCT06672172). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - OUTSTAND-1 (HRS-7535-301, NCT06672172): 60 mg | pop t2d | 32 wk | n=284 | HbA1c pp -1.38 vs -0.18 | AE d/c % 2.9 vs 0 | status easd | src EASD 2026 LBA 39: HRS-7535 monotherapy, OUTSTAND-1 phase 3 (NCT06672172). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - OUTSTAND-2 (HRS-7535-302, NCT06589765): 30 mg | pop t2d | 32 wk | n=810 | HbA1c pp -1.58 vs None | AE d/c % 4.0 vs None | status press | src EASD 2026 LBA 10: HRS-7535 vs dapagliflozin, OUTSTAND-2 phase 3 (NCT06589765). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07 https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535 - OUTSTAND-2 (HRS-7535-302, NCT06589765): 60 mg | pop t2d | 32 wk | n=810 | HbA1c pp -1.5 vs None | AE d/c % 3.9 vs None | status press | src EASD 2026 LBA 10: HRS-7535 vs dapagliflozin, OUTSTAND-2 phase 3 (NCT06589765). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07 https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535 - HARBOR-1 (HRS-7535-303, NCT06904105): 120 mg | pop obesity | 44 wk | n=556 | weight eff -9.5 vs -2.5 % | weight tp -8.0 vs -2.4 % | AE d/c % 4.1 vs 2.7 | nausea % 70.3 vs 16.2 | vomiting % 66.7 vs 4.5 | status press | src Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07 https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535 - HARBOR-1 (HRS-7535-303, NCT06904105): 180 mg | pop obesity | 44 wk | n=556 | weight eff -10.9 vs -2.5 % | weight tp -9.8 vs -2.4 % | AE d/c % 3.1 vs 2.7 | nausea % 70.0 vs 16.2 | vomiting % 68.6 vs 4.5 | status press | src Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07 https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535 - HRS-7535 phase 2 (add-on to metformin + SGLT2i): HRS-7535 30 mg | pop t2d | 16 wk | n=51 | HbA1c pp -1.5 vs -0.4 | AE d/c % 0.0 vs 2.0 | nausea % 15.7 vs 2.0 | vomiting % 13.7 vs 2.0 | SAE % 7.8 vs 0.0 | status verified-2 | src Xu M et al. Diabetologia 2026 https://pubmed.ncbi.nlm.nih.gov/42875600/ - HRS-7535 phase 2 (add-on to metformin + SGLT2i): HRS-7535 60 mg | pop t2d | 16 wk | n=53 | weight (estimand n/s) -2.4 vs -0.7 % | HbA1c pp -1.8 vs -0.4 | AE d/c % 0.0 vs 2.0 | nausea % 21.2 vs 2.0 | vomiting % 19.2 vs 2.0 | SAE % 3.8 vs 0.0 | status verified-2 | src Xu M et al. Diabetologia 2026 https://pubmed.ncbi.nlm.nih.gov/42875600/ ### Dulaglutide (Trulicity) — https://docs.mdwrt.app/infographics/incretin-atlas/dulaglutide/ Mechanism: GLP-1. Route: s.c.. Company: Eli Lilly. Stage: None. Status: Approved (T2D); not developed for obesity. Next: —. - CVOT REWIND (T2D, broad CV risk, n=9901, 2019): 3-point MACE HR 0.88 (0.79–0.99); Cardiovascular death HR 0.91 (0.78–1.06); All-cause death HR 0.9 (0.8–1.01); Myocardial infarction HR 0.96 (0.79–1.15); Stroke HR 0.76 (0.62–0.94); Hospitalisation for heart failure HR 0.93 (0.77–1.12); Kidney composite HR 0.85 (0.77–0.93); Retinopathy complications HR 1.24 (0.92–1.68); Hospitalisation for unstable angina HR 1.14 (0.84–1.54) | src https://pubmed.ncbi.nlm.nih.gov/31189511/ ### Efpeglenatide (Hanmi / Sanofi) — https://docs.mdwrt.app/infographics/incretin-atlas/efpeglenatide/ Mechanism: GLP-1. Route: s.c.. Company: Hanmi. Stage: None. Status: Positive CVOT (AMPLITUDE-O); development paused. Next: —. - CVOT AMPLITUDE-O (T2D + CVD/CKD, n=4076, 2021): 3-point MACE HR 0.73 (0.58–0.92); Cardiovascular death HR 0.72 (0.5–1.03); All-cause death HR 0.78 (0.58–1.06); Myocardial infarction HR 0.75 (0.54–1.05); Stroke HR 0.74 (0.47–1.17); Hospitalisation for heart failure HR 0.61 (0.38–0.98); Kidney composite HR 0.68 (0.57–0.79); Expanded MACE (MACE + revasc. + UA) HR 0.79 (0.65–0.96); New macroalbuminuria HR 0.68 (0.58–0.8); Coronary revascularisation HR 0.93 (0.69–1.26); Hospitalisation for unstable angina HR 0.55 (0.13–2.35) | src https://pubmed.ncbi.nlm.nih.gov/34215025/ ### Albiglutide (Tanzeum (withdrawn)) — https://docs.mdwrt.app/infographics/incretin-atlas/albiglutide/ Mechanism: GLP-1. Route: s.c.. Company: GSK. Stage: None. Status: Withdrawn from market (2018) despite positive CVOT. Next: —. - CVOT Harmony Outcomes (T2D + CVD, n=9463, 2018): 3-point MACE HR 0.78 (0.68–0.9); 4-point MACE HR 0.78 (0.69–0.9); Cardiovascular death HR 0.93 (0.73–1.19); All-cause death HR 0.95 (0.79–1.16); Myocardial infarction HR 0.75 (0.61–0.9); Stroke HR 0.86 (0.66–1.14); CV death or worsening HF HR 0.85 (0.7–1.04); Expanded MACE (MACE + revasc. + UA) HR 0.78 (0.69–0.9) | src https://pubmed.ncbi.nlm.nih.gov/30291013/ ### Exenatide (Bydureon / Byetta) — https://docs.mdwrt.app/infographics/incretin-atlas/exenatide/ Mechanism: GLP-1. Route: s.c.. Company: AstraZeneca. Stage: None. Status: Approved (T2D). Next: —. - CVOT EXSCEL (T2D, broad CV risk, n=14752, 2017): 3-point MACE HR 0.91 (0.83–1.0); Cardiovascular death HR 0.88 (0.76–1.02); All-cause death HR 0.86 (0.77–0.97); Myocardial infarction HR 0.97 (0.85–1.1); Stroke HR 0.85 (0.7–1.03); Hospitalisation for heart failure HR 0.94 (0.78–1.13); Coronary revascularisation HR 0.94 (0.85–1.05) | src https://pubmed.ncbi.nlm.nih.gov/28910237/ ### Lixisenatide (Lyxumia / Adlyxin) — https://docs.mdwrt.app/infographics/incretin-atlas/lixisenatide/ Mechanism: GLP-1. Route: s.c.. Company: Sanofi. Stage: None. Status: Approved (T2D); neutral CVOT. Next: —. - CVOT ELIXA (T2D after ACS, n=6068, 2015): 4-point MACE HR 1.02 (0.89–1.17); Cardiovascular death HR 0.98 (0.78–1.22); All-cause death HR 0.94 (0.78–1.13); Myocardial infarction HR 1.03 (0.87–1.22); Stroke HR 1.12 (0.79–1.58); Hospitalisation for heart failure HR 0.96 (0.75–1.23); Expanded MACE (MACE + HF hosp. + revasc. + UA) HR 1.0 (0.9–1.11); Expanded MACE (MACE + HF hosp. + UA) HR 0.97 (0.85–1.1); Hospitalisation for unstable angina HR 1.11 (0.47–2.62) | src https://pubmed.ncbi.nlm.nih.gov/26630143/ ### VK2735 (Viking Therapeutics) — https://docs.mdwrt.app/infographics/incretin-atlas/vk2735/ Mechanism: GIP/GLP-1. Route: s.c. / oral. Company: Viking Therapeutics. Stage: phase 3. Status: Phase 3: s.c. VANQUISH-1/-2 (since 2025); oral SUNRISE-1/-2 started Oct 2026 (obesity with and without T2D); VENTURE s.c. phase 2 published (Obesity 2026). Next: VANQUISH readouts; SUNRISE enrolment. Indications: Obesity: 2 (phase 3 ongoing) — VANQUISH phase 3 ongoing; T2D: 2 (phase 3 ongoing) — VANQUISH 2 ongoing; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - VENTURE (phase 2, s.c.): VK2735 5.0 mg weekly | pop obesity | 13 wk | n=35 | weight eff -10.9 vs -1.7 % | HbA1c pp -0.27 vs 0.03 | AE d/c % 11.0 vs 0.0 | any d/c % 11.0 vs 14.0 | nausea % 46.0 vs 20.0 | vomiting % 17.0 vs 0.0 | SAE % 6.0 vs 3.0 | SBP mmHg -6.71 vs -4.2 | status verified-2 | src VENTURE, Obesity 2026 https://pubmed.ncbi.nlm.nih.gov/41508550/ - VENTURE (phase 2, s.c.): VK2735 10 mg weekly | pop obesity | 13 wk | n=36 | weight eff -12.9 vs -1.7 % | HbA1c pp -0.27 vs 0.03 | AE d/c % 11.0 vs 0.0 | any d/c % 14.0 vs 14.0 | nausea % 37.0 vs 20.0 | vomiting % 17.0 vs 0.0 | SAE % 6.0 vs 3.0 | SBP mmHg -7.04 vs -4.2 | status verified-2 | src VENTURE, Obesity 2026 https://pubmed.ncbi.nlm.nih.gov/41508550/ - VENTURE (phase 2, s.c.): VK2735 15 mg weekly | pop obesity | 13 wk | n=35 | weight eff -14.7 vs -1.7 % | HbA1c pp -0.36 vs 0.03 | AE d/c % 20.0 vs 0.0 | any d/c % 20.0 vs 14.0 | nausea % 63.0 vs 20.0 | vomiting % 29.0 vs 0.0 | SAE % 3.0 vs 3.0 | SBP mmHg -10.97 vs -4.2 | status verified-2 | src VENTURE, Obesity 2026 https://pubmed.ncbi.nlm.nih.gov/41508550/ - VENTURE-Oral (phase 2): oral VK2735 90 mg daily | pop obesity | 13 wk | n=40 | weight (estimand n/s) -11.1 vs -1.3 % | any d/c % 25.0 vs 18.0 | status verified-2 | src Viking Therapeutics. Viking Therapeutics announces positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity [press release]. San Diego (CA): Viking Therapeutics; 2025 Aug 19 https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-With-Obesity - VENTURE-Oral (phase 2): oral VK2735 120 mg daily | pop obesity | 13 wk | n=40 | weight (estimand n/s) -12.2 vs -1.3 % | any d/c % 38.0 vs 18.0 | status verified-2 | src Viking Therapeutics. Viking Therapeutics announces positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity [press release]. San Diego (CA): Viking Therapeutics; 2025 Aug 19 https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-With-Obesity ### Berobenatide (MET-097i) (Metsera (Pfizer)) — https://docs.mdwrt.app/infographics/incretin-atlas/berobenatide/ Mechanism: GLP-1 (ultra-long-acting, monthly). Route: s.c. monthly. Company: Pfizer (Metsera). Stage: phase 3. Status: Phase 3 started 2026 (monthly dosing); phase 2b VESPER reported 2025. Next: Phase 3; combination with amylin MET-233i. Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 ongoing (monthly dosing); T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 ongoing; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### CT-996 (Roche / Carmot) — https://docs.mdwrt.app/infographics/incretin-atlas/ct-996/ Mechanism: GLP-1 (small molecule). Route: oral. Company: Roche. Stage: phase 2. Status: Phase 2. Next: Phase 2 readout. ### Aleniglipron (GSBR-1290, Structure Therapeutics) — https://docs.mdwrt.app/infographics/incretin-atlas/aleniglipron/ Mechanism: GLP-1 (small molecule). Route: oral. Company: Structure Therapeutics. Stage: phase 3. Status: Two pivotal phase 3 trials (obesity; obesity with or without T2D) recruiting since Jul 2026; phase 2b ACCESS reported 2025. Next: Phase 3 results (primary completion Sep 2028). - ACCESS (phase 2b): aleniglipron 45 mg | pop obesity | 36 wk | n=45 | weight eff -9.0 vs -0.8 % | weight tp -8.8 vs -1.0 % | HbA1c pp -0.27 vs 0.01 | AE d/c % 13.3 vs 5.4 | any d/c % 26.7 vs 25.0 | nausea % 71.1 vs 21.4 | vomiting % 40.0 vs 5.4 | SAE % 2.2 vs 5.4 | SBP mmHg -7.9 vs -1.5 | status verified-2 | src Rosenstock J et al. Nat Med 2026 (ACCESS) https://pubmed.ncbi.nlm.nih.gov/42249138/ - ACCESS (phase 2b): aleniglipron 90 mg | pop obesity | 36 wk | n=65 | weight eff -10.7 vs -0.8 % | weight tp -10.2 vs -1.0 % | HbA1c pp -0.32 vs 0.01 | AE d/c % 7.7 vs 5.4 | any d/c % 24.6 vs 25.0 | nausea % 67.7 vs 21.4 | vomiting % 44.6 vs 5.4 | SAE % 0.0 vs 5.4 | SBP mmHg -8.9 vs -1.5 | status verified-2 | src Rosenstock J et al. Nat Med 2026 (ACCESS) https://pubmed.ncbi.nlm.nih.gov/42249138/ - ACCESS (phase 2b): aleniglipron 120 mg | pop obesity | 36 wk | n=64 | weight eff -12.1 vs -0.8 % | weight tp -11.4 vs -1.0 % | HbA1c pp -0.36 vs 0.01 | AE d/c % 11.1 vs 5.4 | any d/c % 21.9 vs 25.0 | nausea % 65.1 vs 21.4 | vomiting % 31.7 vs 5.4 | SAE % 6.3 vs 5.4 | SBP mmHg -9.0 vs -1.5 | status verified-2 | src Rosenstock J et al. Nat Med 2026 (ACCESS) https://pubmed.ncbi.nlm.nih.gov/42249138/ ### Dapiglutide (ZP7570, Zealand) — https://docs.mdwrt.app/infographics/incretin-atlas/dapiglutide/ Mechanism: GLP-1/GLP-2. Route: s.c.. Company: Zealand Pharma. Stage: phase 2. Status: Phase 2. Next: Phase 2 readout. ### Danuglipron (PF-06882961, Pfizer) — https://docs.mdwrt.app/infographics/incretin-atlas/danuglipron/ Mechanism: GLP-1 (small molecule). Route: oral. Company: Pfizer. Stage: stopped. Status: Discontinued (2025, liver safety signal). Next: —. ### BGM0504 (BrightGene) — https://docs.mdwrt.app/infographics/incretin-atlas/bgm0504/ Mechanism: GIP/GLP-1. Route: s.c.. Company: BrightGene. Stage: filed. Status: Phase 3 positive in China (52 weeks, up to −19.2 %); NDA accepted (June 2026). Next: China approval. Indications: Obesity: 3 (positive phase 3) — Positive phase 3 in China; NDA accepted June 2026; T2D: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - BGM0504 phase 3 (obesity): BGM0504 15 mg | pop obesity | 52 wk | n=None | weight tp -19.19 vs -3.08 % | AE d/c % 0.7 vs None | status verified-2 | src EASD 2026, abstract LBA 37 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/; BrightGene. 博瑞医药 (688166.SH) 自愿披露关于BGM0504注射液减重适应症III期临床试验数据的公告 (2026-029) [HKEX filing]. 2026-05-05 http://static.cninfo.com.cn/finalpage/2026-05-06/1225277468.PDF; EASD 2026 LBA 37: BGM0504 phase 3 in overweight/obesity (NCT06704581). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - BGM0504 phase 3 (obesity): BGM0504 10 mg | pop obesity | 52 wk | n=None | weight tp -17.27 vs -3.08 % | AE d/c % 1.2 vs None | status verified-2 | src EASD 2026, abstract LBA 37 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/; BrightGene. 博瑞医药 (688166.SH) 自愿披露关于BGM0504注射液减重适应症III期临床试验数据的公告 (2026-029) [HKEX filing]. 2026-05-05 http://static.cninfo.com.cn/finalpage/2026-05-06/1225277468.PDF; EASD 2026 LBA 37: BGM0504 phase 3 in overweight/obesity (NCT06704581). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - BGM0504 phase 3 (obesity): BGM0504 5 mg | pop obesity | 52 wk | n=None | weight tp -14.31 vs -3.08 % | AE d/c % 1.7 vs None | status verified-2 | src EASD 2026, abstract LBA 37 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/; BrightGene. 博瑞医药 (688166.SH) 自愿披露关于BGM0504注射液减重适应症III期临床试验数据的公告 (2026-029) [HKEX filing]. 2026-05-05 http://static.cninfo.com.cn/finalpage/2026-05-06/1225277468.PDF; EASD 2026 LBA 37: BGM0504 phase 3 in overweight/obesity (NCT06704581). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - BGM0504 phase 2 (China, obesity): BGM0504 5 mg | pop obesity | 24 wk | n=None | weight (estimand n/s) -10.68 vs 0.13 % | status verified-2 | src BGM0504 phase 2, 2026 https://pubmed.ncbi.nlm.nih.gov/42755112/ - BGM0504 phase 2 (China, obesity): BGM0504 10 mg | pop obesity | 24 wk | n=None | weight (estimand n/s) -16.07 vs 0.13 % | status verified-2 | src BGM0504 phase 2, 2026 https://pubmed.ncbi.nlm.nih.gov/42755112/ - BGM0504 phase 2 (China, obesity): BGM0504 15 mg | pop obesity | 24 wk | n=None | weight (estimand n/s) -18.33 vs 0.13 % | status verified-2 | src BGM0504 phase 2, 2026 https://pubmed.ncbi.nlm.nih.gov/42755112/ ### HDM1702 (Zhongmei Huadong) — https://docs.mdwrt.app/infographics/incretin-atlas/hdm1702/ Mechanism: GLP-1. Route: s.c.. Company: Huadong Medicine. Stage: filed. Status: Semaglutide follow-on: phase 3 equivalence to Wegovy; NDAs accepted in China (T2D Mar 2025; weight Apr 2026). Next: China approval. Indications: Obesity: 3 (positive phase 3) — Phase 3 equivalence versus Wegovy met (semaglutide follow-on); T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - HDM1702 vs Wegovy (bioequivalence): HDM1702 2.4 mg | pop obesity | 44 wk | n=462 | weight tp -15.24 vs None % | status easd | src EASD 2026, abstract 594 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/ ### HDM1005 (Huadong) — https://docs.mdwrt.app/infographics/incretin-atlas/hdm1005/ Mechanism: GIP/GLP-1. Route: s.c.. Company: Huadong Medicine. Stage: phase 3. Status: Phase 3 in China (obesity; T2D; head-to-head vs mazdutide in T2D) since Oct 2025; phase 2 T2D (20 wk) at EASD 2026: HbA1c up to −2.57 %. Next: Phase 3 obesity results (primary completion Sep 2026). Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; T2D: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - HDM1005 phase 2 (T2D): HDM1005 3.0 mg | pop t2d | 20 wk | n=220 | weight eff -5.89 vs -0.17 % | HbA1c pp -2.57 vs -0.57 | status verified-2 | src EASD 2026, abstract 782 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/ - China Phase II (obesity, non-diabetic): 2.0 mg | pop obesity | 22 wk | n=243 | weight (estimand n/s) -13.31 vs -2.46 % | status press | src Huadong Medicine. 华东医药HDM1005注射液减重II期临床告捷 (Pharnexcloud news, Chinese) [secondary]. 2025-12-15 https://www.pharnexcloud.com/zixun/shiye/lcyj_261317 - China Phase II (obesity, non-diabetic): 4.0 mg | pop obesity | 22 wk | n=243 | weight (estimand n/s) -13.28 vs -2.46 % | status press | src Huadong Medicine. 华东医药HDM1005注射液减重II期临床告捷 (Pharnexcloud news, Chinese) [secondary]. 2025-12-15 https://www.pharnexcloud.com/zixun/shiye/lcyj_261317 ### RAY1225 (Raynovent) — https://docs.mdwrt.app/infographics/incretin-atlas/ray1225/ Mechanism: GIP/GLP-1. Route: s.c. every 2 weeks. Company: Raynovent. Stage: phase 3. Status: Phase 3 REBUILDING-2 positive (9 mg every 2 weeks: −22.2 % at 52 weeks, topline Oct 2026); licensed to Qilu. Next: NDA in China. Indications: Obesity: 3 (positive phase 3) — Positive phase 3 REBUILDING-2 (topline Oct 2026); T2D: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - Shining-1 (T2D): RAY1225 15 mg every 2 weeks | pop t2d | 24 wk | n=None | HbA1c pp -2.76 vs -0.25 | SBP mmHg -7.8 vs 0.0 | status verified-2 | src EASD 2026, abstract 16 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/; EASD 2026 abstract: RAY1225 Shining-1 phase 2 in T2D (NCT06254274). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - REBUILDING-2 (RAY1225, NCT06893016): 9 mg Q2W | pop obesity | 52 wk | n=641 | weight eff -22.3 vs None % | weight tp -22.24 vs None % | status press | src Raynovent / Zhongsheng. 众生药业 (002317.SZ) 关于控股子公司一类创新药RAY1225注射液减重III期临床试验获得顶线分析数据结果的公告 (2026-068) [HKEX filing]. 2026-10-08 http://static.cninfo.com.cn/finalpage/2026-10-09/1225597551.PDF - REBUILDING-1 (RAY1225, NCT06254261): 3 mg Q2W | pop obesity | 24 wk | n=172 | weight (estimand n/s) -10.05 vs -3.55 % | status press | src Raynovent / Zhongsheng. 众生药业 (002317.SZ) 关于控股子公司一类创新药RAY1225注射液II期临床试验获得顶线分析数据结果的公告 (2025-045) [HKEX filing]. 2025-05-06 http://static.cninfo.com.cn/finalpage/2025-05-07/1223477369.PDF - REBUILDING-1 (RAY1225, NCT06254261): 6 mg Q2W | pop obesity | 24 wk | n=172 | weight (estimand n/s) -12.98 vs -3.55 % | status press | src Raynovent / Zhongsheng. 众生药业 (002317.SZ) 关于控股子公司一类创新药RAY1225注射液II期临床试验获得顶线分析数据结果的公告 (2025-045) [HKEX filing]. 2025-05-06 http://static.cninfo.com.cn/finalpage/2025-05-07/1223477369.PDF - REBUILDING-1 (RAY1225, NCT06254261): 9 mg Q2W | pop obesity | 24 wk | n=172 | weight (estimand n/s) -15.05 vs -3.55 % | status press | src Raynovent / Zhongsheng. 众生药业 (002317.SZ) 关于控股子公司一类创新药RAY1225注射液II期临床试验获得顶线分析数据结果的公告 (2025-045) [HKEX filing]. 2025-05-06 http://static.cninfo.com.cn/finalpage/2025-05-07/1223477369.PDF - SHINING-1 (RAY1225, NCT06254274): 3 mg Q2W | pop t2d | 24 wk | n=231 | HbA1c pp -1.66 vs -0.25 | status easd | src EASD 2026 abstract: RAY1225 Shining-1 phase 2 in T2D (NCT06254274). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - SHINING-1 (RAY1225, NCT06254274): 6 mg Q2W | pop t2d | 24 wk | n=231 | HbA1c pp -2.04 vs -0.25 | status easd | src EASD 2026 abstract: RAY1225 Shining-1 phase 2 in T2D (NCT06254274). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - SHINING-1 (RAY1225, NCT06254274): 9 mg Q2W | pop t2d | 24 wk | n=231 | HbA1c pp -2.14 vs -0.25 | status easd | src EASD 2026 abstract: RAY1225 Shining-1 phase 2 in T2D (NCT06254274). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ - SHINING-1 (RAY1225, NCT06254274): 12 mg Q2W | pop t2d | 24 wk | n=231 | HbA1c pp -2.34 vs -0.25 | status easd | src EASD 2026 abstract: RAY1225 Shining-1 phase 2 in T2D (NCT06254274). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/ ### TG103 (CSPC) — https://docs.mdwrt.app/infographics/incretin-atlas/tg103/ Mechanism: GLP-1. Route: s.c.. Company: CSPC. Stage: filed. Status: Efmedaglutide alfa. Phase 3 T2D non-inferior to dulaglutide; obesity NDA accepted in China (Oct 2025). Next: China approval. Indications: Obesity: 2 (phase 3 ongoing) — Obesity NDA accepted in China (Oct 2025); phase 3 numbers not published; T2D: 3 (positive phase 3) — Phase 3 non-inferiority versus dulaglutide met; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - TG103 phase 3 vs dulaglutide (T2D): TG103 15 mg | pop t2d | 28 wk | n=None | HbA1c pp -1.38 vs None | status easd | src EASD 2026, abstract 836 (China pipeline page) https://docs.mdwrt.app/infographics/china-incretin-pipeline-easd-2026/ - Phase III TG103 + metformin vs dulaglutide (EASD 2026): 15 mg QW | pop t2d | 52 wk | n=211 | HbA1c pp -1.31 vs None | status press | src CSPC. CSPC voluntary announcement: Results of Phase III study of Efmedaglutide Alfa (TG103) + metformin in Chinese adults with T2DM presented at EASD 2026 [HKEX filing]. 2026-09-30 https://doc.irasia.com/listco/hk/cspc/announcement/a260930.pdf ### Bofanglutide (GZR18) (Gan & Lee) — https://docs.mdwrt.app/infographics/incretin-atlas/bofanglutide/ Mechanism: GLP-1. Route: s.c. every 2 weeks. Company: Gan & Lee. Stage: phase 3. Status: Phase 3 GRADUAL-1 positive (48 mg every 2 weeks: −18.5 % at 52 weeks); US phase 2; once-monthly GRADUAL-3 started. Next: NDA in China. Indications: Obesity: 3 (positive phase 3) — Positive phase 3 GRADUAL-1 (52 weeks); GRADUAL-3 once-monthly maintenance after GRADUAL-1: weight +0.41 % / −0.12 % vs +8.52 % with placebo over 24 weeks (topline release, November 2026); T2D: 2 (phase 3 ongoing) — Phase 3 ongoing; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 2 (phase 3 ongoing) — Phase 3 ongoing; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - Phase 2b CTR20231695: 12 mg Q2W | pop obesity | 30 wk | n=52 | weight (estimand n/s) -11.15 vs -0.99 % | SAE % 0 vs None | status press | src Gan & Lee. ObesityWeek 2024: Gan & Lee orally presents Phase 2b clinical data for GZR18 injection in Chinese overweight and obese adults (BioSpace mirror of PR Newswire) [press release]. 2024-11-11 https://www.biospace.com/press-releases/obesityweek-2024-gan-lee-pharmaceuticals-orally-presents-phase-2b-clinical-data-for-gzr18-injection-in-chinese-overweight-and-obese-adults - Phase 2b CTR20231695: 18 mg Q2W | pop obesity | 30 wk | n=53 | weight (estimand n/s) -13.22 vs -0.99 % | SAE % 0 vs None | status press | src Gan & Lee. ObesityWeek 2024: Gan & Lee orally presents Phase 2b clinical data for GZR18 injection in Chinese overweight and obese adults (BioSpace mirror of PR Newswire) [press release]. 2024-11-11 https://www.biospace.com/press-releases/obesityweek-2024-gan-lee-pharmaceuticals-orally-presents-phase-2b-clinical-data-for-gzr18-injection-in-chinese-overweight-and-obese-adults - Phase 2b CTR20231695: 24 mg Q2W | pop obesity | 30 wk | n=52 | weight (estimand n/s) -14.25 vs -0.99 % | SAE % 0 vs None | status press | src Gan & Lee. ObesityWeek 2024: Gan & Lee orally presents Phase 2b clinical data for GZR18 injection in Chinese overweight and obese adults (BioSpace mirror of PR Newswire) [press release]. 2024-11-11 https://www.biospace.com/press-releases/obesityweek-2024-gan-lee-pharmaceuticals-orally-presents-phase-2b-clinical-data-for-gzr18-injection-in-chinese-overweight-and-obese-adults - Phase 2b CTR20231695: 48 mg Q2W | pop obesity | 30 wk | n=64 | weight (estimand n/s) -17.29 vs -0.99 % | SAE % 0 vs None | status press | src Gan & Lee. ObesityWeek 2024: Gan & Lee orally presents Phase 2b clinical data for GZR18 injection in Chinese overweight and obese adults (BioSpace mirror of PR Newswire) [press release]. 2024-11-11 https://www.biospace.com/press-releases/obesityweek-2024-gan-lee-pharmaceuticals-orally-presents-phase-2b-clinical-data-for-gzr18-injection-in-chinese-overweight-and-obese-adults - Phase 2b CTR20231695: 24 mg QW | pop obesity | 30 wk | n=53 | weight (estimand n/s) -17.78 vs -0.99 % | SAE % 0 vs None | status press | src Gan & Lee. ObesityWeek 2024: Gan & Lee orally presents Phase 2b clinical data for GZR18 injection in Chinese overweight and obese adults (BioSpace mirror of PR Newswire) [press release]. 2024-11-11 https://www.biospace.com/press-releases/obesityweek-2024-gan-lee-pharmaceuticals-orally-presents-phase-2b-clinical-data-for-gzr18-injection-in-chinese-overweight-and-obese-adults - Phase 2b CTR20232069 (vs semaglutide): 12 mg Q2W | pop t2d | 24 wk | n=264 | HbA1c pp -1.87 vs None | status press | src Gan & Lee. Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18, GZR4 and GZR101 Achieve Primary Endpoints in Phase 2 Clinical Studies (BioSpace mirror of PR Newswire/CNW) [press release]. 2024-10-15 https://www.biospace.com/press-releases/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and-gzr101-injection-achieve-primary-endpoints-in-phase-2-clinical-studies - Phase 2b CTR20232069 (vs semaglutide): 18 mg Q2W | pop t2d | 24 wk | n=264 | HbA1c pp -2.28 vs None | status press | src Gan & Lee. Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18, GZR4 and GZR101 Achieve Primary Endpoints in Phase 2 Clinical Studies (BioSpace mirror of PR Newswire/CNW) [press release]. 2024-10-15 https://www.biospace.com/press-releases/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and-gzr101-injection-achieve-primary-endpoints-in-phase-2-clinical-studies - Phase 2b CTR20232069 (vs semaglutide): 24 mg Q2W | pop t2d | 24 wk | n=264 | HbA1c pp -1.94 vs None | status press | src Gan & Lee. Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18, GZR4 and GZR101 Achieve Primary Endpoints in Phase 2 Clinical Studies (BioSpace mirror of PR Newswire/CNW) [press release]. 2024-10-15 https://www.biospace.com/press-releases/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and-gzr101-injection-achieve-primary-endpoints-in-phase-2-clinical-studies - Phase 2b CTR20232069 (vs semaglutide): 24 mg QW | pop t2d | 24 wk | n=264 | HbA1c pp -2.32 vs None | status press | src Gan & Lee. Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18, GZR4 and GZR101 Achieve Primary Endpoints in Phase 2 Clinical Studies (BioSpace mirror of PR Newswire/CNW) [press release]. 2024-10-15 https://www.biospace.com/press-releases/gan-lee-pharmaceuticals-three-innovative-drugs-gzr18-injection-gzr4-injection-and-gzr101-injection-achieve-primary-endpoints-in-phase-2-clinical-studies - GRADUAL-1 (NCT06728124): 24 mg Q2W | pop obesity | 52 wk | n=640 | weight (estimand n/s) -15.12 vs -1.11 % | status press | src Gan & Lee. Gan & Lee: Insulin Ludefen meets Phase III endpoint; Bofanglutide meets primary endpoints in Phase III weight-loss study in China (GRADUAL-1) and Phase II in the U.S. (Macau Business mirror of PR Newswire) [press release]. 2026-06-12 https://macaubusiness.com/gan-lee-pharmaceuticals-achieves-significant-progress-in-its-dual-pipeline-for-metabolic-diseases-weekly-insulin-ludefen-gzr4-meets-primary-endpoint-in-phase-iii-clinical-trial-in-china-bo/ - GRADUAL-1 (NCT06728124): 48 mg Q2W | pop obesity | 52 wk | n=640 | weight (estimand n/s) -18.54 vs -1.11 % | status press | src Gan & Lee. Gan & Lee: Insulin Ludefen meets Phase III endpoint; Bofanglutide meets primary endpoints in Phase III weight-loss study in China (GRADUAL-1) and Phase II in the U.S. (Macau Business mirror of PR Newswire) [press release]. 2026-06-12 https://macaubusiness.com/gan-lee-pharmaceuticals-achieves-significant-progress-in-its-dual-pipeline-for-metabolic-diseases-weekly-insulin-ludefen-gzr4-meets-primary-endpoint-in-phase-iii-clinical-trial-in-china-bo/ - US Phase 2 (NCT06737042): 48 mg Q2W | pop obesity | 36 wk | n=326 | weight (estimand n/s) -15.18 vs None % | status press | src Gan & Lee. Gan & Lee: Insulin Ludefen meets Phase III endpoint; Bofanglutide meets primary endpoints in Phase III weight-loss study in China (GRADUAL-1) and Phase II in the U.S. (Macau Business mirror of PR Newswire) [press release]. 2026-06-12 https://macaubusiness.com/gan-lee-pharmaceuticals-achieves-significant-progress-in-its-dual-pipeline-for-metabolic-diseases-weekly-insulin-ludefen-gzr4-meets-primary-endpoint-in-phase-iii-clinical-trial-in-china-bo/ ### HRS-4729 (Hengrui) — https://docs.mdwrt.app/infographics/incretin-atlas/hrs-4729/ Mechanism: GIP/GLP-1/GCG. Route: s.c.. Company: Hengrui. Stage: phase 2. Status: Phase 2 master protocol in MASH recruiting since Aug 2026; phase 1 at EASD 2026. Next: Phase 2 results. - HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600): 12 mg | pop obesity | 12 wk | n=60 | weight (estimand n/s) -16.0 vs -5.4 % | status press | src Kailera. Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates (8-K Ex. 99.1) [press release]. 2026-05-26 https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/ck0002096997-ex99_1.htm ### DD1013 (Huadong) — https://docs.mdwrt.app/infographics/incretin-atlas/dd1013/ Mechanism: GLP-1 + GIP + amylin (triple). Route: s.c.. Company: Huadong Medicine. Stage: preclinical. Status: Preclinical (EASD 2026). Next: Phase 1. ### ASC35 / ASC36 (Ascletis) — https://docs.mdwrt.app/infographics/incretin-atlas/asc35-asc36/ Mechanism: GIP/GLP-1 + amylin (monthly co-formulation). Route: s.c. monthly. Company: Ascletis. Stage: phase 1. Status: Phase 1 single and multiple ascending dose study recruiting since Aug 2026; preclinical data at EASD 2026. Next: Phase 1 results. ### HS-20094 (Hansoh (Regeneron licence ex-China)) — https://docs.mdwrt.app/infographics/incretin-atlas/hs-20094/ Mechanism: GIP/GLP-1. Route: s.c.. Company: Hansoh. Stage: filed. Status: Olatorepatide. Phase 3 LIGHTEN positive in China (−18.7 % at 48 weeks, EASD 2026); NDA accepted (June 2026); Regeneron licence ex-China. Next: China approval; global phase 3 (Regeneron). Indications: Obesity: 3 (positive phase 3) — Positive phase 3 LIGHTEN (EASD 2026); NDA accepted June 2026; T2D: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - LIGHTEN (HS-20094-301): 5 mg | pop obesity | 48 wk | n=604 | weight eff -12.5 vs -2.7 % | weight tp -11.8 vs -2.5 % | status easd | src EASD 2026 LBA 27: Efficacy and safety of olatorepatide ... phase 3 study (LIGHTEN). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Hansoh Pharma. Olatorepatide phase III LIGHTEN data presented at EASD 2026 [EQS-News]. 2026 Oct 2 https://www.boersennews.de/nachrichten/meldungen/eqs/eqs-news-19-3-weight-loss-at-week-48-phase-data-of-olatorepatide-hansoh-s-dual-biased-glp-1-gip-agonist-presented-at-easd/5297659/ - LIGHTEN (HS-20094-301): 10 mg | pop obesity | 48 wk | n=604 | weight eff -17.5 vs -2.7 % | weight tp -17.0 vs -2.5 % | status easd | src EASD 2026 LBA 27: Efficacy and safety of olatorepatide ... phase 3 study (LIGHTEN). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Hansoh Pharma. Olatorepatide phase III LIGHTEN data presented at EASD 2026 [EQS-News]. 2026 Oct 2 https://www.boersennews.de/nachrichten/meldungen/eqs/eqs-news-19-3-weight-loss-at-week-48-phase-data-of-olatorepatide-hansoh-s-dual-biased-glp-1-gip-agonist-presented-at-easd/5297659/ - LIGHTEN (HS-20094-301): 15 mg | pop obesity | 48 wk | n=604 | weight eff -19.3 vs -2.7 % | weight tp -18.7 vs -2.5 % | status easd | src EASD 2026 LBA 27: Efficacy and safety of olatorepatide ... phase 3 study (LIGHTEN). EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/; Hansoh Pharma. Olatorepatide phase III LIGHTEN data presented at EASD 2026 [EQS-News]. 2026 Oct 2 https://www.boersennews.de/nachrichten/meldungen/eqs/eqs-news-19-3-weight-loss-at-week-48-phase-data-of-olatorepatide-hansoh-s-dual-biased-glp-1-gip-agonist-presented-at-easd/5297659/ ### ASC30 (Ascletis (oral small molecule and injectable)) — https://docs.mdwrt.app/infographics/incretin-atlas/asc30/ Mechanism: GLP-1 (small molecule). Route: oral / s.c.. Company: Ascletis. Stage: phase 3. Status: Oral phase 2 (13 weeks: placebo-adjusted −7.7 %); global phase 3 AURORA started (Aug 2026). Next: Phase 3. Indications: Obesity: 2 (phase 3 ongoing) — Oral phase 2 positive (13 weeks); phase 3 AURORA started Aug 2026; T2D: 2 (phase 3 ongoing) — U.S. phase 2 topline (company release, October 2026): HbA1c 1.6–1.7 points and weight 3.8–4.4 % below placebo at 12–13 weeks; phase 3 registered on ClinicalTrials.gov; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### HDM1002 (Zhongmei Huadong) — https://docs.mdwrt.app/infographics/incretin-atlas/hdm1002/ Mechanism: GLP-1 (small molecule). Route: oral. Company: Huadong Medicine. Stage: phase 3. Status: Phase 3 HDM1002-301 positive (oral; up to −12.2 % efficacy estimand at 52 weeks); pre-NDA. Next: NDA in China. Indications: Obesity: 3 (positive phase 3) — Positive phase 3 HDM1002-301 (oral); T2D: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - HDM1002-301: 200 mg QD | pop obesity | 52 wk | n=857 | weight eff -10.7 vs -1.5 % | weight tp -9.4 vs -1.5 % | AE d/c % 1.5 vs 0.6 | status press | src Huadong Medicine (Zhongmei Huadong). 华东医药 公告2026-057: HDM1002片减重Ⅲ期研究(HDM1002-301)获得积极顶线结果 (SZSE filing, Chinese) [HKEX filing]. 2026-09-28 http://static.cninfo.com.cn/finalpage/2026-09-28/1225583787.PDF - HDM1002-301: 400 mg QD | pop obesity | 52 wk | n=857 | weight eff -12.2 vs -1.5 % | weight tp -11.3 vs -1.5 % | AE d/c % 2.0 vs 0.6 | status press | src Huadong Medicine (Zhongmei Huadong). 华东医药 公告2026-057: HDM1002片减重Ⅲ期研究(HDM1002-301)获得积极顶线结果 (SZSE filing, Chinese) [HKEX filing]. 2026-09-28 http://static.cninfo.com.cn/finalpage/2026-09-28/1225583787.PDF ### AZD5004 (ECC5004) (Eccogene → AstraZeneca) — https://docs.mdwrt.app/infographics/incretin-atlas/azd5004/ Mechanism: GLP-1 (small molecule). Route: oral. Company: AstraZeneca (Eccogene). Stage: phase 3. Status: Elecoglipron. Phase 2b VISTA (obesity) and SOLSTICE (T2D) positive; phase 3 started (June 2026). Next: Phase 3 readouts. Indications: Obesity: 2 (phase 3 ongoing) — Phase 2b VISTA positive; phase 3 started June 2026; T2D: 2 (phase 3 ongoing) — Phase 2b SOLSTICE positive; phase 3 ongoing; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - VISTA (NCT06579092): 5 mg QD | pop obesity | 36 wk | n=310 | weight eff -2.7 vs -0.6 % | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385 - VISTA (NCT06579092): 15 mg QD | pop obesity | 36 wk | n=310 | weight eff -6.5 vs -0.6 % | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385 - VISTA (NCT06579092): 50 mg QD (escalated every 4 weeks) | pop obesity | 36 wk | n=310 | weight eff -9.2 vs -0.6 % | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385 - VISTA (NCT06579092): 75 mg QD (escalated weekly) | pop obesity | 36 wk | n=310 | weight eff -11.8 vs -0.6 % | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385 - VISTA (NCT06579092): 75 mg QD (escalated every 2 weeks) | pop obesity | 36 wk | n=310 | weight eff -11.1 vs -0.6 % | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385 - SOLSTICE (NCT06579105): 5 mg QD | pop t2d | 26 wk | n=406 | weight eff -2.9 vs -1.7 % | HbA1c pp -0.91 vs -0.15 | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385; SOLSTICE, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42259343/ - SOLSTICE (NCT06579105): 15 mg QD | pop t2d | 26 wk | n=406 | weight eff -3.4 vs -1.7 % | HbA1c pp -1.1 vs -0.15 | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385; SOLSTICE, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42259343/ - SOLSTICE (NCT06579105): 25 mg QD | pop t2d | 26 wk | n=406 | weight eff -4.0 vs -1.7 % | HbA1c pp -1.2 vs -0.15 | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385; SOLSTICE, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42259343/ - SOLSTICE (NCT06579105): 50 mg QD (escalated every 2 weeks) | pop t2d | 26 wk | n=406 | weight eff -5.9 vs -1.7 % | HbA1c pp -1.4 vs -0.15 | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385; SOLSTICE, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42259343/ - SOLSTICE (NCT06579105): 75 mg QD (escalated every 2 weeks) | pop t2d | 26 wk | n=406 | weight eff -7.7 vs -1.7 % | HbA1c pp -1.88 vs -0.15 | nausea % 37 vs 3 | vomiting % 18 vs 1 | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385; SOLSTICE, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42259343/ - SOLSTICE (NCT06579105): 75 mg QD (escalated every 4 weeks) | pop t2d | 26 wk | n=406 | weight eff -7.0 vs -1.7 % | HbA1c pp -1.6 vs -0.15 | status press | src AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08 https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385; SOLSTICE, Lancet 2026 https://pubmed.ncbi.nlm.nih.gov/42259343/ ### DR10624 (Zhejiang Doer Biologics) — https://docs.mdwrt.app/infographics/incretin-atlas/dr10624/ Mechanism: GLP-1/GCG/FGF21. Route: s.c.. Company: Doer Biologics. Stage: phase 3. Status: Phase 3 in severe hypertriglyceridaemia; obesity/MASH in development. Next: Phase 3 readout (sHTG). Indications: Obesity: 0 (no data) — ; T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 1 (phase 2 / signal) — Phase 2 only; HFpEF: 0 (no data) — ; MASH: 1 (phase 2 / signal) — Phase 2 only; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### Efsubaglutide alfa (supaglutide) (Yinnuo / Innogen) — https://docs.mdwrt.app/infographics/incretin-atlas/efsubaglutide-alfa/ Mechanism: GLP-1. Route: s.c. weekly. Company: Yinnuo (Innogen). Stage: approved. Status: Approved in China for T2D (January 2025); obesity phase 2b ENLIGHT positive; obesity phase 3 topline expected end-2026. Next: Obesity phase 3. Indications: Obesity: 2 (phase 3 ongoing) — Phase 2b ENLIGHT positive; phase 3 topline expected end-2026; T2D: 4 (approved / in label) — NMPA (China), January 2025; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - ENLIGHT Phase IIb (NCT06921486): 20 mg QW | pop obesity | 18 wk | n=200 | weight (estimand n/s) -10.58 vs None % | status press | src Innogen (Yinnuo). Innogen to present Phase IIb ENLIGHT study results for Efsubaglutide Alfa at ADA 2026 (BioSpace mirror of PR Newswire) [press release]. 2026-05-29 https://www.biospace.com/press-releases/innogen-to-present-phase-iib-enlight-study-results-for-efsubaglutide-alfa-at-the-2026-ada-scientific-sessions - ENLIGHT Phase IIb (NCT06921486): 20 mg Q2W | pop obesity | 18 wk | n=200 | weight (estimand n/s) -9.7 vs None % | status press | src Innogen (Yinnuo). Innogen to present Phase IIb ENLIGHT study results for Efsubaglutide Alfa at ADA 2026 (BioSpace mirror of PR Newswire) [press release]. 2026-05-29 https://www.biospace.com/press-releases/innogen-to-present-phase-iib-enlight-study-results-for-efsubaglutide-alfa-at-the-2026-ada-scientific-sessions - SUPER 2 (NCT04998032), phase 3 stage: 3 mg QW | pop t2d | 24 wk | n=171 | HbA1c pp -1.8 vs -0.74 | nausea % 7.6 vs 4.0 | vomiting % 9.9 vs 1.7 | status press | src Innogen (Yinnuo). Efsubaglutide alfa added to metformin in T2D: randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). Nat Commun 2026 [publication]. 2026-05-08 https://www.nature.com/articles/s41467-026-72574-7 - SUPER 2 (NCT04998032), phase 2b stage: 1 mg QW | pop t2d | 12 wk | n=120 | HbA1c pp -1.1 vs None | status press | src Innogen (Yinnuo). Efsubaglutide alfa added to metformin in T2D: randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). Nat Commun 2026 [publication]. 2026-05-08 https://www.nature.com/articles/s41467-026-72574-7 - SUPER 2 (NCT04998032), phase 2b stage: 3 mg QW | pop t2d | 12 wk | n=120 | HbA1c pp -1.43 vs None | status press | src Innogen (Yinnuo). Efsubaglutide alfa added to metformin in T2D: randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). Nat Commun 2026 [publication]. 2026-05-08 https://www.nature.com/articles/s41467-026-72574-7 ### PB-119 (PegBio (PEGylated exenatide)) — https://docs.mdwrt.app/infographics/incretin-atlas/pb-119/ Mechanism: GLP-1. Route: s.c. weekly. Company: PegBio. Stage: approved. Status: Approved in China for T2D (November 2025). Next: Obesity development. Indications: Obesity: 1 (phase 2 / signal) — Phase 2 only; T2D: 4 (approved / in label) — NMPA (China), November 2025; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - Phase 3 monotherapy (NCT04504370): 150 μg QW | pop t2d | 24 wk | n=137 | HbA1c pp -1.36 vs -0.63 | AE d/c % 2.2 vs None | any d/c % 4.4 vs 7.4 | nausea % 8.0 vs 0.7 | vomiting % 5.8 vs 0.0 | SAE % 6.6 vs 1.5 | status press | src PegBio. Efficacy and safety of visepegenatide (PB-119) as monotherapy in T2DM: phase 3 RCT. Lancet Reg Health West Pac 2024;47:101101 [publication]. 2024-06 https://pmc.ncbi.nlm.nih.gov/articles/PMC11214404/ - Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197): 150 μg QW | pop t2d | 24 wk | n=310 | HbA1c pp -1.25 vs -0.68 | any d/c % 7.4 vs 7.7 | nausea % 4.2 vs 0.3 | vomiting % 4.8 vs 0.3 | SAE % 2.9 vs 3.9 | status press | src PegBio. Efficacy and safety of visepegenatide (PB-119) as add-on to metformin in T2DM: phase 3 RCT. Lancet Reg Health West Pac 2024;51:101197 [publication]. 2024-10 https://pmc.ncbi.nlm.nih.gov/articles/PMC11488426/ ### PEG-loxenatide (Hansoh (Fulaimei)) — https://docs.mdwrt.app/infographics/incretin-atlas/peg-loxenatide/ Mechanism: GLP-1. Route: s.c. weekly. Company: Hansoh. Stage: approved. Status: Approved in China for T2D (May 2019, Fulaimei). Next: —. Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 registered on ClinicalTrials.gov; T2D: 4 (approved / in label) — NMPA (China), May 2019 (Fulaimei); CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - PEX168 monotherapy phase 3a: 100 μg | pop t2d | 24 wk | n=361 | HbA1c pp -1.02 vs -0.17 | AE d/c % 1.6 vs 0.8 | nausea % 5.6 vs 0 | vomiting % 2.4 vs 0 | status press | src Hansoh. PEG-loxenatide monotherapy in type 2 diabetes: phase 3a trial, Diabetes Obes Metab 2021 [publication]. 2020-10-08 https://pubmed.ncbi.nlm.nih.gov/32965075/ - PEX168 monotherapy phase 3a: 200 μg | pop t2d | 24 wk | n=361 | HbA1c pp -1.34 vs -0.17 | AE d/c % 2.5 vs 0.8 | nausea % 10.0 vs 0 | vomiting % 8.3 vs 0 | status press | src Hansoh. PEG-loxenatide monotherapy in type 2 diabetes: phase 3a trial, Diabetes Obes Metab 2021 [publication]. 2020-10-08 https://pubmed.ncbi.nlm.nih.gov/32965075/ - PEX168 add-on to metformin phase 3b: 100 μg + metformin | pop t2d | 24 wk | n=None | HbA1c pp -1.16 vs None | SAE % 0 vs 0 | status press | src Hansoh. PEG-loxenatide add-on to metformin in type 2 diabetes: phase 3b trial, Diabetes Obes Metab 2020 [publication]. 2020-09-06 https://pubmed.ncbi.nlm.nih.gov/32744358/ - PEX168 add-on to metformin phase 3b: 200 μg + metformin | pop t2d | 24 wk | n=None | HbA1c pp -1.14 vs None | SAE % 0 vs 0 | status press | src Hansoh. PEG-loxenatide add-on to metformin in type 2 diabetes: phase 3b trial, Diabetes Obes Metab 2020 [publication]. 2020-09-06 https://pubmed.ncbi.nlm.nih.gov/32744358/ ### Beinaglutide (Benemae) — https://docs.mdwrt.app/infographics/incretin-atlas/beinaglutide/ Mechanism: GLP-1. Route: s.c. daily. Company: Benemae. Stage: approved. Status: Approved in China: T2D (2016), weight management (2023). Next: —. Indications: Obesity: 4 (approved / in label) — NMPA (China), weight management, July 2023; T2D: 4 (approved / in label) — NMPA (China), 2016; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — - Phase 3 weight management (ChiCTR1900023428): 0.2 mg TID | pop obesity | 16 wk | n=282 | weight (estimand n/s) -6.0 vs -2.4 % | AE d/c % 5.9 vs 0.7 | nausea % 49.3 vs 7.1 | status press | src Shanghai Benemae. Chen K et al. Beinaglutide for weight management in Chinese individuals with overweight or obesity: phase 3 RCT. Diabetes Obes Metab 2024;26:690-698 (PubMed abstract) [publication]. 2023-11-09 https://pubmed.ncbi.nlm.nih.gov/37945546/ ### HEC88473 (HEC) — https://docs.mdwrt.app/infographics/incretin-atlas/hec88473/ Mechanism: GLP-1/FGF21. Route: s.c.. Company: HEC. Stage: phase 2. Status: Phase 2. Next: Phase 2 readout. Indications: Obesity: 0 (no data) — ; T2D: 1 (phase 2 / signal) — Phase 2 only; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### Zovaglutide (ZT002, QL Biopharm) — https://docs.mdwrt.app/infographics/incretin-atlas/zovaglutide/ Mechanism: GLP-1 (ultra-long-acting, monthly). Route: s.c.. Company: QL Biopharm. Stage: phase 3. Status: Phase 3 in obesity (HORIZON-1, China, started Jan 2026). Next: HORIZON-1 readout. Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 HORIZON-1 (China) ongoing; phase 2 met its primary endpoint (company, 2025); T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### Noiiglutide (SHR20004 / HS-20004, Hengrui) — https://docs.mdwrt.app/infographics/incretin-atlas/noiiglutide/ Mechanism: GLP-1. Route: s.c.. Company: Hengrui. Stage: phase 3. Status: Phase 3 in T2D (China) completed; results not yet public. Next: T2D results / filing. Indications: Obesity: 1 (phase 2 / signal) — Phase 2 in obesity without diabetes; T2D: 2 (phase 3 ongoing) — Phase 3 vs placebo (24 weeks) completed; results not yet public; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### Lenbelintide (AZD6234, AstraZeneca) — https://docs.mdwrt.app/infographics/incretin-atlas/lenbelintide/ Mechanism: Amylin. Route: s.c.. Company: AstraZeneca. Stage: phase 3. Status: Phase 3 recruiting (adjunct to incretin-based therapy, 68 weeks). Next: Phase 3 readout. Indications: Obesity: 2 (phase 3 ongoing) — Phase 3 recruiting: adjunct to incretin-based therapy, 68 weeks; T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### Efocipegtrutide (HM15211, Hanmi) — https://docs.mdwrt.app/infographics/incretin-atlas/efocipegtrutide/ Mechanism: GIP/GLP-1/GCG. Route: s.c.. Company: Hanmi. Stage: phase 2. Status: Phase 2 in biopsy-confirmed MASH. Next: Phase 2 results. Indications: Obesity: 0 (no data) — ; T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 1 (phase 2 / signal) — Phase 2 in biopsy-confirmed MASH; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### Macupatide (LY3532226, Eli Lilly) — https://docs.mdwrt.app/infographics/incretin-atlas/macupatide/ Mechanism: GIP. Route: s.c.. Company: Eli Lilly. Stage: phase 2. Status: Phase 2 (alone and with eloralintide). Next: Phase 2 results. Indications: Obesity: 1 (phase 2 / signal) — Phase 2, alone and with eloralintide; T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 0 (no data) — ; HFpEF: 0 (no data) — ; MASH: 0 (no data) — ; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### Cotadutide (MEDI0382, AstraZeneca) — https://docs.mdwrt.app/infographics/incretin-atlas/cotadutide/ Mechanism: GLP-1/GCG. Route: s.c.. Company: AstraZeneca. Stage: phase 2. Status: Phase 2 (MASH, CKD with T2D) completed; no phase 3 registered. Next: —. Indications: Obesity: 0 (no data) — ; T2D: 0 (no data) — ; CV outcomes: 0 (no data) — ; CKD: 1 (phase 2 / signal) — Phase 2 in CKD with T2D; HFpEF: 0 (no data) — ; MASH: 1 (phase 2 / signal) — Phase 2 in NASH with fibrosis; Sleep apnoea: 0 (no data) — ; Knee OA: 0 (no data) — ; Alzheimer's: 0 (no data) — ### EloraTZP (eloralintide + tirzepatide, Eli Lilly) — https://docs.mdwrt.app/infographics/incretin-atlas/eloratzp/ Mechanism: GIP/GLP-1 + amylin. Route: s.c.. Company: Eli Lilly. Stage: phase 3. Status: Phase 2b in obesity with T2D positive (Sep 2026: up to −23.3 % vs −14.8 % with tirzepatide 15 mg); phase 3 AMPLIFY-1 and AMPLIFY-2 registered (100 weeks, start Q4 2026). Next: AMPLIFY phase 3 start. - EloraTZP phase 2b (obesity + T2D): EloraTZP 3/5 mg | pop t2d | 48 wk | n=None | weight eff -13.2 vs -3.0 % | HbA1c pp -2.2 vs -0.3 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html - EloraTZP phase 2b (obesity + T2D): EloraTZP 6/5 mg | pop t2d | 48 wk | n=None | weight eff -19.4 vs -3.0 % | HbA1c pp -2.7 vs -0.3 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html - EloraTZP phase 2b (obesity + T2D): EloraTZP 6/10 mg | pop t2d | 48 wk | n=None | weight eff -19.9 vs -3.0 % | HbA1c pp -2.6 vs -0.3 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html - EloraTZP phase 2b (obesity + T2D): EloraTZP 9/15 mg | pop t2d | 48 wk | n=None | weight eff -23.3 vs -3.0 % | HbA1c pp -2.9 vs -0.3 | status press | src Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30 https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html ## Trials - STEP 1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-1/ - STEP UP: https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-up/ - STEP 2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-2/ - OASIS 4: https://docs.mdwrt.app/infographics/incretin-atlas/trials/oasis-4/ - SURMOUNT-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-1/ - SURMOUNT-2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-2/ - SURMOUNT-5 (head-to-head): https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-5/ - Retatrutide phase 2 (obesity): https://docs.mdwrt.app/infographics/incretin-atlas/trials/retatrutide-phase-2-obesity/ - Retatrutide phase 2 (T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/retatrutide-phase-2-t2d/ - TRANSCEND-T2D-1 (T2D monotherapy): https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-1/ - REDEFINE 1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-1/ - REDEFINE 2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-2/ - REIMAGINE 1 (early T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/reimagine-1/ - Survodutide phase 2 (obesity): https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2/ - Amycretin s.c. phase 1b/2a: https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-s-c-phase-1b-2a/ - Amycretin oral phase 1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/amycretin-oral-phase-1/ - ATTAIN-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-1/ - ATTAIN-2 (obesity + T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-2/ - ACHIEVE-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-1/ - MOMENTUM: https://docs.mdwrt.app/infographics/incretin-atlas/trials/momentum/ - CT-388 phase 2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-phase-2/ - RGT-075 phase 2b: https://docs.mdwrt.app/infographics/incretin-atlas/trials/rgt-075-phase-2b/ - Ribupatide phase 2 (obesity + PMOS): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-phase-2/ - BGM0504 phase 3 (obesity): https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-3/ - HDM1702 vs Wegovy (bioequivalence): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1702-vs-wegovy/ - Shining-1 (T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/shining-1/ - HDM1005 phase 2 (T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1005-phase-2/ - OUTSTAND-1 (early T2D, monotherapy): https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-1/ - TG103 phase 3 vs dulaglutide (T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/tg103-phase-3-vs-dulaglutide/ - TRIUMPH-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1/ - SYNCHRONIZE-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-1/ - REDEFINE 5 (vs semaglutide 2.4 mg): https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-5/ - VENTURE (phase 2, s.c.): https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture/ - Zenagamtide s.c. phase 2 (T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/zenagamtide-s-c-phase-2/ - VENTURE-Oral (phase 2): https://docs.mdwrt.app/infographics/incretin-atlas/trials/venture-oral/ - TRIUMPH-4 (obesity + knee osteoarthritis): https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4/ - UBT251 phase 2 (obesity): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity/ - UBT251 phase 2 (T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-t2d/ - US phase 2 (NCT06124807): https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06124807/ - DREAMS-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-1/ - DREAMS-3: https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-3/ - SLIMMER: https://docs.mdwrt.app/infographics/incretin-atlas/trials/slimmer/ - SLIMMER-UP-SWITCH (interim): https://docs.mdwrt.app/infographics/incretin-atlas/trials/slimmer-up-switch/ - EECOH-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/eecoh-1/ - EECOH-2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/eecoh-2/ - LIGHTEN (HS-20094-301): https://docs.mdwrt.app/infographics/incretin-atlas/trials/lighten/ - PEX168 monotherapy phase 3a: https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-monotherapy-phase-3a/ - PEX168 add-on to metformin phase 3b: https://docs.mdwrt.app/infographics/incretin-atlas/trials/pex168-add-on-to-metformin-phase-3b/ - HRS9531-301 (GEMINI-1, NCT06396429): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-301/ - HRS9531-203 (NCT06054698): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-203/ - HRS9531-201 (NCT05881837): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-201/ - HRS9531-T-201 oral ribupatide (NCT06841445): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs9531-t-201-oral-ribupatide/ - Ribupatide in obesity + PMOS (NCT06595797): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-in-obesity-pmos/ - Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ribupatide-t2d-phase-3-after-metformin-sglt2i/ - OUTSTAND-2 (HRS-7535-302, NCT06589765): https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-2/ - HARBOR-1 (HRS-7535-303, NCT06904105): https://docs.mdwrt.app/infographics/incretin-atlas/trials/harbor-1/ - HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-4729-phase-1-sad-mad-mad-part/ - UBT251 phase 2 obesity China (NCT07177469): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity-china/ - UBT251 phase 2 T2D China (NCT07163624): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-t2d-china/ - REBUILDING-2 (RAY1225, NCT06893016): https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-2/ - REBUILDING-1 (RAY1225, NCT06254261): https://docs.mdwrt.app/infographics/incretin-atlas/trials/rebuilding-1/ - Phase 2b CTR20231695: https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20231695/ - Phase 2b CTR20232069 (vs semaglutide): https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20232069/ - GRADUAL-1 (NCT06728124): https://docs.mdwrt.app/infographics/incretin-atlas/trials/gradual-1/ - US Phase 2 (NCT06737042): https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06737042/ - Phase III TG103 + metformin vs dulaglutide (EASD 2026): https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-iii-tg103-metformin-vs-dulaglutide/ - HDM1002-301: https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1002-301/ - China Phase II (obesity, non-diabetic): https://docs.mdwrt.app/infographics/incretin-atlas/trials/china-phase-ii/ - VISTA (NCT06579092): https://docs.mdwrt.app/infographics/incretin-atlas/trials/vista/ - SOLSTICE (NCT06579105): https://docs.mdwrt.app/infographics/incretin-atlas/trials/solstice/ - ENLIGHT Phase IIb (NCT06921486): https://docs.mdwrt.app/infographics/incretin-atlas/trials/enlight-phase-iib/ - SUPER 2 (NCT04998032), phase 3 stage: https://docs.mdwrt.app/infographics/incretin-atlas/trials/super-2-phase-3-stage/ - Phase 3 monotherapy (NCT04504370): https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-monotherapy/ - Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197): https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-add-on-to-metformin/ - Phase 3 weight management (ChiCTR1900023428): https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-weight-management/ - TRIUMPH-2 (obesity + T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-2/ - SYNCHRONIZE-2 (obesity + T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-2/ - ZUPREME-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/zupreme-1/ - ZUPREME-2 (obesity + T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/zupreme-2/ - REIMAGINE 5 (vs tirzepatide 5 mg): https://docs.mdwrt.app/infographics/incretin-atlas/trials/reimagine-5/ - REDEFINE 9: https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-9/ - EloraTZP phase 2b (obesity + T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/eloratzp-phase-2b/ - CT-388-104 (T2D): https://docs.mdwrt.app/infographics/incretin-atlas/trials/ct-388-104/ - BGM0504 phase 2 (China, obesity): https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-2/ - ACHIEVE-2 (vs dapagliflozin): https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-2/ - GLORY-1: https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-1/ - GLORY-2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-2/ - DREAMS-2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/dreams-2/ - ACCESS (phase 2b): https://docs.mdwrt.app/infographics/incretin-atlas/trials/access/ - HRS-7535 phase 2 (add-on to metformin + SGLT2i): https://docs.mdwrt.app/infographics/incretin-atlas/trials/hrs-7535-phase-2/ - MariTide phase 2 (obesity cohort): https://docs.mdwrt.app/infographics/incretin-atlas/trials/maritide-phase-2/ - TRANSCEND-T2D-2 (vs semaglutide 2 mg): https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-2/ - ATTAIN-J (Japan): https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-j/ - SYNCHRONIZE-CVOT: https://docs.mdwrt.app/infographics/incretin-atlas/trials/synchronize-cvot/ - SELECT: https://docs.mdwrt.app/infographics/incretin-atlas/trials/select/ - FLOW: https://docs.mdwrt.app/infographics/incretin-atlas/trials/flow/ - SOUL: https://docs.mdwrt.app/infographics/incretin-atlas/trials/soul/ - SUSTAIN-6: https://docs.mdwrt.app/infographics/incretin-atlas/trials/sustain-6/ - PIONEER 6: https://docs.mdwrt.app/infographics/incretin-atlas/trials/pioneer-6/ - LEADER: https://docs.mdwrt.app/infographics/incretin-atlas/trials/leader/ - SURPASS-CVOT: https://docs.mdwrt.app/infographics/incretin-atlas/trials/surpass-cvot/ - SUMMIT: https://docs.mdwrt.app/infographics/incretin-atlas/trials/summit/ - REWIND: https://docs.mdwrt.app/infographics/incretin-atlas/trials/rewind/ - AMPLITUDE-O: https://docs.mdwrt.app/infographics/incretin-atlas/trials/amplitude-o/ - Harmony Outcomes: https://docs.mdwrt.app/infographics/incretin-atlas/trials/harmony-outcomes/ - EXSCEL: https://docs.mdwrt.app/infographics/incretin-atlas/trials/exscel/ - ELIXA: https://docs.mdwrt.app/infographics/incretin-atlas/trials/elixa/ - ACHIEVE-4: https://docs.mdwrt.app/infographics/incretin-atlas/trials/achieve-4/ - STEP-HFpEF: https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef/ - STEP-HFpEF DM: https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-hfpef-dm/ - SURMOUNT-OSA: https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-osa/ - STEP 9: https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-9/ - ESSENCE (part 1): https://docs.mdwrt.app/infographics/incretin-atlas/trials/essence/ - SYNERGY-NASH: https://docs.mdwrt.app/infographics/incretin-atlas/trials/synergy-nash/ - Survodutide phase 2 MASH: https://docs.mdwrt.app/infographics/incretin-atlas/trials/survodutide-phase-2-mash/ - evoke / evoke+: https://docs.mdwrt.app/infographics/incretin-atlas/trials/evoke-evoke/ - ELAD: https://docs.mdwrt.app/infographics/incretin-atlas/trials/elad/ - TRIUMPH-1-OSA / TRIUMPH-2-OSA: https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-1-osa-triumph-2-osa/ - TRIUMPH-4 / TRIUMPH-1-OA: https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4-triumph-1-oa/ - ATTAIN-OSA trial 1 / trial 2: https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-osa-trial-1-trial-2/ - Phase 2b: https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b/ - IMPACT: https://docs.mdwrt.app/infographics/incretin-atlas/trials/impact/ - SURMOUNT-MMO: https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-mmo/ - REDEFINE 3: https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-3/ - TRIUMPH-OUTCOMES: https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-outcomes/ - Orforglipron CVOT: https://docs.mdwrt.app/infographics/incretin-atlas/trials/orforglipron-cvot/ - MARITIME-CV: https://docs.mdwrt.app/infographics/incretin-atlas/trials/maritime-cv/